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The characteristics of South Africa’s HIV epidemic mean that approximately 28% of women presenting 
for antenatal care, are HIV-infected. Maternal HIV-infection can lead to mother-to-child transmission 
(MTCT) of HIV during pregnancy, labour, delivery or breastfeeding if viral load (VL) is not well controlled 
by antiretroviral therapy (ART). Globally, 90% of pediatric infections occur via MTCT, though lifelong ART 
is reducing the rate of new infections. Full benefits of ART can only be realized when ART adherence is 
high. Evidence from South Africa and elsewhere has shown that ART adherence in pregnant and 
postpartum women is suboptimal. Potential drivers of suboptimal adherence may include poor or 
inadequate knowledge of HIV and ART. This thesis investigates how HIV-infected pregnant and 
postpartum women’s knowledge of HIV and ART-related information may be associated with ART 
adherence as evaluated by HIV VL measures.  
Components of this thesis include the research protocol, a literature review of previous studies 
exploring the relationship between knowledge and HIV-related health outcomes in Sub-Saharan Africa 
and a manuscript describing the results of an investigation into predictors of HIV and ART-related 
knowledge and the association of knowledge with maternal vireamia (VL>1000copies/mL). 
This data for analysis came from a cohort of 376 HIV-infected pregnant women, initiating ART during 
pregnancy, at a primary care antenatal facility in Gugulethu, South Africa. Participants were followed 
from their first antenatal visit until twelve months postpartum. Knowledge of HIV and ART-related 
information were assessed at three time points by two knowledge inventories and items were classified 
as either relating to general knowledge or prevention of MTCT. HIV VL was measured at delivery and 
twelve months postpartum.  Demographic characteristics were surveyed at the first antenatal visit.  
Analyses included univariable and multivariable regression models to estimate potential predictors of 
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knowledge among demographic and clinical characteristics, as well as to estimate the association 
between knowledge and maternal vireamia at delivery and twelve months postpartum.  
We found that HIV and ART knowledge increased marginally over the repeated study visits. Knowledge 
relating to general HIV or ART information was typically good while knowledge on PMTCT was lacking. 
Education (OR=-0.52; 95% CI=-0.83- -0.21; P=0.001), previous HIV diagnoses (OR=-0.36; 95% CI=-0.09-
0.63; P=0.009), and weeks on ART at delivery (OR=-0.03; 95% CI=0.00-0.06; P=0.047) were statistically 
significant predictors of HIV knowledge in adjusted analyses. The associations between the various 
knowledge outcomes and vireamia at delivery and twelve months postpartum were mixed and generally 
not statistically significant.  
In summary, HIV and ART knowledge both increased with increasing time in care and general knowledge 
was better than knowledge specific to MTCT. Education, timing of HIV diagnoses and time on ART were 
identified as potential predictors of HIV-related knowledge. Generally, knowledge of HIV or ART was not 
meaningfully associated with vireamia at delivery or at twelve months postpartum. There remain 
significant gaps in the knowledge of HIV-infected women, of childbearing age, around how HIV is 
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BACKGROUND & RATIONALE 
To date, HIV/AIDS is still one of the largest global public health concerns with an estimated 36.7 million 
people living with HIV in 2015 (1). To combat the AIDS epidemic, the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) has set a new target (2). The goal is to ensure that by 2020; 90% of HIV-infected 
individuals are aware of their HIV status,  90% of these individuals are on lifelong antiretroviral therapy 
(ART) and 90% of those receiving ART are virally suppressed (2). It has been suggested, that if these 
targets are achieved, the AIDS epidemic can come to an end by 2030, resulting in major health and 
economic gains (2).  
Achievement of the aforementioned goal hinges on the availability of HIV treatment to all those in need 
(2).  One target population of particular interest is HIV-infected pregnant women and their HIV-exposed 
infants (1).  The maternal care platform remains one of the most robust in Sub-Saharan Africa and many 
HIV-infected women are first identified during pregnancy. Moreover, the vast majority of  the estimated 
1.8 million children living with HIV, became infected as a result of mother-to-child transmission (MTCT) 
(vertical transmission), during pregnancy, labour, birth or breastfeeding (1). Prevention of mother-to-
child transmission (PMTCT) is thus of major concern.  
MTCT rates can be as high as 45% but with the use of successful interventions, transmission rates below 
5% are achievable (3). The ultimate goal is to eliminate all MTCT and in some countries, such as Thailand 
and Belarus,  this is already a reality (4). The use of combination ART during pregnancy, birth and the 
postpartum breastfeeding period has proved extremely effective for PMTC T (3). Intervention strategies 
thus primarily focus on ART and significant efforts have been made to reduce vertical transmission by 
extensive ART scale-up for pregnant women (3). Although HIV/AIDS is a global epidemic, individuals in 
low-and-middle-income countries are disproportionately affected (1) and 90% of HIV-infected children 
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reside in the countries of Sub-Saharan Africa (4). In South Africa specifically, a  vertical transmission rate 
of 3.5%  has been reported (28).  
Total elimination of MTCT cannot be achieved solely through increased availability of ART.  We need to 
consider that ART effectiveness is directly dependent on ART adherence which refers to taking correct 
medication doses at correct times in the correct manner (5). Studies have demonstrated that for ART to 
be clinically efficacious, an adherence rate of at least 95% is necessary (6). Without optimal ART 
adherence, drug resistant strains of HIV may develop but moreover HIV viral load (VL) cannot be 
suppressed (7). This is of particular concern for HIV-infected pregnant women because failure to 
suppress VL significantly increases the risk of MTCT (8).  
It is, therefore, critical that mothers and their infants remain engaged in the full cascade of care, from 
entry into PMTCT services to infant HIV testing through to maternal re-entry into adult ART services (8). 
Despite significant efforts to eliminate MTCT and major advances in the cascade of PMTCT and ART 
services, ART adherence in pregnant and postpartum women is still suboptimal (9).  As such, research on 
the determinants of ART adherence will be crucial in moving forward to realize the goal of eliminating 
vertical transmission. Various studies have sought to uncover both barriers to and enablers of ART 
adherence during pregnancy and the postpartum period (10). Barriers and enablers identified in the 
Sub-Saharan African setting include but are not limited to: age, fear, HIV-related stigma, access to health 
services, self-efficacy, HIV status disclosure, social support, education and knowledge of HIV and/or ART 
(10). These barriers and enablers have been researched to variable extents and further advancements 
are still required (10).  
Of particular interest is the influence of knowledge on maternal ART adherence since improved 
knowledge can be easily achieved through educational programme interventions  (11). The possible 
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mechanism by which knowledge may influence health outcomes is explained by the knowledge-attitude-
behaviour/practice (KAB/P) model (12). Here knowledge refers to gaining information that can be used 
to make decisions, attitude refers to favourable or unfavourable feelings towards something and 
practice refers to behaviours that avert or delay disease (13). This model postulates that both 
knowledge and attitude can directly affect behaviour in a gradual manner (14).  As an individual gains 
knowledge, their attitude changes (14). Over time these changes can accumulate and act as a 
motivational driver for behavior change (14). It is possible that HIV-infected pregnant and postpartum 
women who have sufficient knowledge about HIV and ART have more favourable attitudes towards 
health-seeking and health-promoting behaviour. They may, therefore, have increased motivation to 
behave in ways that lead to positive health outcomes.   
In the Sub-Saharan African setting, few studies have investigated the relationship between HIV and ART-
related knowledge and maternal health with inconclusive results. Studies in Ghana, Malawi, Kenya and 
South Africa have found associations between adequate knowledge and improved maternal health 
outcomes (5,15–17). Studies in Uganda, Ethiopia, Nigeria, Zimbabwe and additional South African 
studies have, however, found no evidence of similar associations (18–25). Health outcomes examined in 
these studies included access to ART, uptake of ART, use of antenatal services, retention in care and loss 
to follow-up, ART adherence and PMTCT and transmission risk behaviours (5,15–25). No studies have 
investigated the relationship between knowledge of HIV and ART-related information and maternal VL. 
A study of this nature would be particularly valuable since VL is the key outcome measure of ART and 
long-term health as well as the driving force behind MTCT risk (8,26). 
In light of poor ART adherence and retention in PMTCT services in South Africa as well as research gaps, 
the Maternal & Child Health Antiretroviral Therapy (MCH-ART) study is underway (8). The MCH-ART 
study is set in Gugulethu, located in Cape Town, South Africa and aims to optimize ART services for 
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mothers and their infants (8). The study involves the assessment of HIV-infected pregnant women 
during antenatal and postnatal periods as well as their HIV-exposed infants (8). A wide array of 
measurements has been collected from this population including data on knowledge and VL (8). Cohort-
specific vertical transmission risk has been documented at 1.3% and is significantly associated with 
increased VL (27). VL in this context can capture the essence of PMTCT service functioning, individual 
level behaviors including adherence as well as treatment effectiveness in a real setting (8). It has 
therefore been stated that VL is the most appropriate ART-related outcome measure in this setting (8).  
Given the above, it is clear that more research on HIV-related knowledge and ART adherence in HIV-
infected pregnant women in South Africa is warranted. It is also clear that VL is a key robust measure, 
encompassing ART adherence in this context. Moreover, VL has not been investigated as an outcome 
measure in any Sub-Saharan African knowledge association studies. A cohort of HIV-infected pregnant 
women from South Africa with data on HIV-related knowledge and VL is available. This provides the 
perfect opportunity for such research to be conducted.   
AIMS & OBJECTIVES  
Aim: 
The overall aim of this study is to determine whether knowledge influences ART outcomes in women 
who initiate ART during pregnancy. 
Objectives:  
This study has three main objectives which are as follows: 
1. To identify potential predictors of maternal HIV and ART knowledge.  
2. To determine if knowledge of HIV influences maternal ART adherence as assessed by viral load. 
6 
 
3. To determine if knowledge of ART influences maternal ART adherence as assessed by viral load. 
A priori hypotheses: 
Regarding objectives 2 and 3, we hypothesize that: 
 Increased knowledge of HIV is associated with improved ART adherence indicated by reduced 
viral load.   
 Increased knowledge of ART is associated with improved ART adherence indicated by reduced 
viral load.  
STUDY DESIGN  
In order to address the study objectives, previously collected data will be analyzed (secondary data 
analysis). The parent study of this research is the MCH-ART study which aims to optimize ART services 
for maternal and child health by addressing several complex objectives (8). To achieve these objectives, 
MCH-ART followed HIV-infected pregnant women throughout antenatal and postnatal periods (8). Three 
different study designs, each represented by their own phase were employed (Figure A1) and are 
described below. In addition, the analysis set that will be utilized by the current study, including all three 
MCH-ART phases, is described.  
Phase 1 
Phase 1 was a cross-sectional study of consecutive HIV-infected pregnant women attending their first 
antenatal visit. The purpose of this phase was to assess the health statuses of and services received by 
HIV-infected pregnant women at the study clinic. Participants attended only one study visit at which 




Phase 2 was an observational cohort study including women from phase 1 who, according to local 
guidelines, were eligible to initiate ART. The purpose of this phase was to describe ART initiation as well 
as antenatal follow-up in the study population. In this phase, participants were followed from their 
second antenatal visit until their first postpartum visit and were assessed at three time points. 
Assessments took place at their second antenatal visit, in the third trimester of pregnancy and within a 
week after delivery (postpartum).  At each study visit women completed relevant questionnaires and 
had blood drawn. 
Phase 3 
Phase 3 was a randomized trial to assess two methods of ART delivery during the postpartum period. It 
included a subset of phase 2 breastfeeding women. In this phase, women were randomized to receive 
either the ART standard of care, where they were referred to general adult ART services at 4-8 weeks 
postpartum, or to receive ART at the antenatal clinic with referral to general adult ART services only 
after breastfeeding had ceased. In this phase participants were assessed at 6 weeks, 3 months, 6 
months, 9 months and 12 months postpartum. At each study visit women completed relevant 




Figure A 1: MCH-ART study design. 
 
 
Analysis set  
The current study will be restricted to participants included in all three phases of the MCH-ART study 
who completed all knowledge-related questionnaires (n=376). The exposure of interest is HIV/ART 
knowledge while the outcome of interest is HIV vireamia (VL > 1000 copies/mL) which will be used to 
assess ART adherence. Moreover, demographic characteristics and participants’ medical history which 
may influence the relationship between knowledge and vireamia are of interest.  
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STUDY POPULATION  
The MCH-ART study enrolled HIV-infected pregnant women seeking antenatal services between April 
2013 and June 2014 at the Gugulethu Midwife Obstetric Unit (MOU) situated at the Gugulethu 
Community Health Centre (CHC) in Cape Town, South Africa. Subgroups of these women were followed 
for extended periods as explained above. The Gugulethu MOU is a primary care facility in a peri-urban 
setting with extensive antenatal care (ANC) coverage (>95 %).  
INCLUSION & EXCLUSION CRITERIA 
Each MCH-ART phase had specific participant inclusion criteria while the exclusion criteria were general.  
Inclusion Criteria 
Phase 1 
Participants must have been: (i) 18 years of age or older, (ii) HIV-infected (as confirmed by two finger 
prick rapid tests in those with unknown infection statuses or documentation of statuses in those who 
self-reported infection status), (iii)pregnant (as confirmed by a urine test, ultrasound or clinical exam), 
(iv) not receiving ART and (v) able to provide informed consent. 
Phase 2 
Participants must: (i) have consented to participate in phase 1, (ii) been eligible to initiate ART according 
to local guidelines, (iii) be initiating ART at the Gugulethu MOU during pregnancy (previous ART 
recipients must not have received treatment for at least six months) and (iv) have been able to provide 




Participants must have: (i) consented to participate in phase 2, (ii) initiated ART in the antenatal period, 
(iii) been breastfeeding, (iv) been willing to participate in the randomization process where they were 
allocated to one of two methods of ART delivery, (v) been willing to take part in postnatal visits and (vi) 
been able to provide informed consent.  
Exclusion Criteria  
Individuals were excluded from participation if they met any of the following criteria: (i) they were not 
pregnant or had experienced a miscarriage when inclusion criteria were assessed, (ii) they planned to 
permanently move out of Cape Town at some point during the study period, (iii) they had any medical, 
psychiatric or social conditions which investigators believed may affect ability to provide informed 
consent and/or efficiently participate in the study where participation barriers included ART refusal or 
HIV status denial. 
RESEARCH PROCEDURES 
All research procedures and data collection processes have already taken place and all data for the 
current study is readily available. All procedures took place during MCH-ART study measurement visits 
which were carried out separate from routine antenatal and postnatal clinic visits. The broad MCH-ART 
study included a multitude of measurements, however, only a small subset of these measurements is of 
interest in the current study. Measurements of interest include: HIV and ART knowledge, VL at delivery 
and 12 months postpartum and demographic characteristics and participants’ medical history. The 




HIV & ART Knowledge  
Knowledge about HIV and ART were assessed and scored by two separate inventories (Appendix A). 
Instruments were administered to participants at the second antenatal visit (visit 2), the six week 
postpartum visit (visit 5) and the nine month postpartum visit (visit 8). Knowledge inventories were 
short and administered to participants along with various other questionnaires and a blood draw. The 
phase 1 study measurement visit had an approximate duration of 20 minutes, phase 2 study visits had 
an approximate duration of 30-45 minutes each and phase 3 study measurement visits had approximate 
durations ranging from 35-60 minutes each. In all instances, the instruments were administered by 
trained interviewers, able to assist participants’ in their home language (isiXhosa).  
HIV Viral Load 
At each study visit (9 in total), 5mL of venous blood was collected from each participant into serum 
separating tubes, via venepuncture. As indicated above, study measurement visits for each phase, which 
included the blood draw, had a minimum duration of 20 minutes and a maximum duration of 60 
minutes.  Blood was transported to the National Health Laboratory Service (NHLS) for batched VL testing 
using the Abbott Molecular RealTime HIV-1 assay (Abbott Molecular, Illinois, USA). All blood draws were 
performed by trained phlebotomists and all VL testing was performed by individuals trained in the 
required laboratory techniques. Furthermore, all blood draws as well as specimen handling, processing, 
and storage was carried out according to routine protocols. Only VL measurements at delivery and at 12 
months postpartum will be used as outcome variables in the current analyses. 
Demographic Characteristics & Medical History 
All demographic characteristics and medical history information was collected at the first study 
measurement visit. This information was collected by means of a short standardized questionnaire as 
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presented in Appendix B. Questionnaires were administered by trained interviewers in participants’ 
home language (isiXhosa).  
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Table A 1: Measurements to be used in the current study and timing of their collection. 
*HIV viral load at <7 days postpartum is considered HIV viral load at delivery  
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RISKS & BENEFITS TO PARTICIPANTS 
Since the current study involves only secondary data analysis, no new risks are posed to participants. 
This study is thus regarded as a minimal risk study. There are no direct benefits to study participants; 
however, identifying the relationships between HIV/ART knowledge and VL/ART adherence has the 
potential to yield indirect benefits. Better understanding of how knowledge affects VL/ART adherence 
may shed light on an important step in the PMTCT cascade which can be targeted for intervention to 
improve PMTCT services.  
INFORMED CONSENT 
All participants were required to sign informed consent, in accordance with the Declaration of Helsinki, 
before enrolling in any phase of the MCH-ART study. As such, three informed consent documents were 
necessary (Appendix C). All documents were verbally delivered to participants by specifically trained 
interviewers, following a standard script in participants’ home-language (isiXhosa). The consent process 
detailed information regarding the study purpose, all study procedures as well as the risks and benefits 
of taking part in the research. During the consent processes and over the course of the study, 
interviewers made participants continuously aware that: (i) study participation was voluntary and would 
in no way affect the care they received and (ii) they could freely withdraw from the study at any time 
and that this would not affect their healthcare in any way. Details of each informed consent process are 
presented below: 
Informed Consent 1  
The first informed consent document was completed by HIV-infected pregnant women who were willing 
and eligible to participate in phase 1 of MCH-ART. This process provided information on the main study 
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purpose as well as information on completing the initial questionnaire (containing demographic and 
behavioral information), the blood draw, granting permission to abstract information from medical 
records and granting permission to be contacted for later research.  
Informed Consent 2 
The second informed consent document was completed by a subset of phase 1 women, eligible to 
initiate ART, who were willing to participate in phase 2 and deemed suitable according to the inclusion 
and exclusion criteria. This process provided information on the overall study purposes as well as 
information on all phase 2 specific procedures. 
Informed Consent 3 
The third informed consent document was completed by a subset of phase 2 breastfeeding women who 
were willing to participate in phase 3 and deemed suitable according to the inclusion and exclusion 
criteria. This process provided information on the overall study purposes as well as information 
pertaining to the two ART delivery methods being tested, the process of randomization and all further 
phase 3 specific procedures. 
PRIVACY & CONFIDENTIALITY  
The MCH-ART study made use of a variety of privacy and confidentiality measures. All pertinent 
measures will be upheld throughout the current study and include: (i) storing all participant information 
in secured cabinets at the Gugulethu study office or at the University of Cape Town, (ii) restricting 
participant identifiers to informed consent forms only accessible by project coordinators or principle 
investigators, (iii) using anonymous study identifiers on all study documents and (iv) ensuring all 




Since the current sub-study involves only secondary data analysis, participants will not receive any 
compensation specific to this study. Participants had, however, already received compensation for 
participation in the MCH-ART study. Participants received R20 per study visit to cover transportation 
costs, grocery vouchers to the value of R80 and refreshments up to the value of R50. 
ANALYTIC CONSIDERATIONS 
Data Source 
All data to be used in the current study is from the MCH-ART study and has been previously collected. 
Sample Size  
The current study’s sample size (n=376) and power is calculated based on the previously collected data 
from the MCH-ART study. The formula used for the power calculation is as follows:                                  
and all parameters are specified below (Table A2). Assuming 20% of HIV-
infected women are vireamic and a standard deviation of 1.3, we can detect a 0.5 unit difference 
between groups with 84.4% power at a 5% significance level (α=0.05).   





Study Parameter Value 
Alpha 0.05 





Mean 1 6.00 
Mean 2 6.50 
Standard deviation  1.30 
Estimated power 0.844 
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Data Analysis  
All data will be analyzed using STATA V14.0 (Stata Corporation, College Station, Texas, USA). The 
characteristics of participants will be described using medians and interquartile ranges (IQR) or by 
frequencies (%).HIV knowledge and ART knowledge will be described by frequencies of item-specific 
correct answers, means of total correct answers and cumulative number correct. Univariable and 
multivariable linear regression models will be used to estimate associations between 
demographic/clinical variables and knowledge scores. Univariable and multivariable logistic regression 
models will be used to estimate associations between knowledge scores and vireamia at delivery and 12 
months postpartum. Coefficients, odds ratios and 95% confidence intervals will be reported. For all 
analyses, statistical significance will be set at α=0.05.  
ETHICAL COMPLIANCE  
Ethical approval was obtained for the MCH-ART study from the Human Research Ethics Committee of 
the Faculty of Health Sciences within the University of Cape Town (HREC: 451/2012) (Appendix D) and 
the Columbia University Medical Centre Institutional Review Board. The current study protocol and 
required documentation will be reviewed and approved by the Human Research Ethics Committee of 
the Faculty of Health Sciences within the University of Cape Town (HREC: 707/2017). As highlighted: (i) 
all participants completed informed consent documents and were aware that they could freely 
withdraw from the study without any repercussions, (ii) this study is considered a minimal risk study in 
which benefits outweigh risks, (iii) extensive measures have and will continue to be taken to assure data 
confidentiality and (iv) participants were not excessively compensated. Furthermore, study collaborators 
will agree on all results to be disseminated and no funding bodies may influence which/how results will 
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In 2015 an estimated 36.7 million people were living with HIV (1).  More than 70% of the HIV-infected 
population resides in Sub-Saharan Africa with the greatest prevalence found in South Africa, where 
women are disproportionately affected (2, 3). Furthermore, it has been noted than among pregnant 
women in this region, approximately 28% are HIV-infected (4). This is of major concern since mother-to-
child transmission (MTCT) accounts for about 90% of new pediatric infections (5).   
HIV-infected women can transmit HIV to their infants during pregnancy, labour, delivery or 
breastfeeding (6). Without preventative measures MTCT rates can be as high as 45% (7). Interventions 
aimed at preventing mother-to-child transmission (PMTCT) can, however,  reduce these rates to <5%  as 
shown in high income countries (7, 66).  In recent years, policy changes increasing the availability of and 
access to maternal antiretroviral therapy (ART) have had a major impact on reducing MTCT (8). Many 
Sub-Saharan African countries, including South Africa, have adopted the World Health Organization’s 
(WHO) “Option B+” strategy which calls for universal initiation of lifelong ART among pregnant and 
breastfeeding women irrespective of CD4 count, stage of disease or gestational age (8,9). Consequently, 
there has been a large increase in women initiating ART during pregnancy and the postpartum period in 
South Africa as the maternal care platform is one of the most robust among Sub-Saharan African 
countries (8).  
The role of ART in maternal health is three-fold: ART improves the health status of the mother, reduces 
the risk of MTCT and reduces the risk of horizontal HIV transmission to sexual partners (10,11). These 
benefits arise because ART acts to suppress viral load (VL) (12). This, however, can only be achieved 
through optimal ART adherence where adherence rates of at least 95% are required for clinical efficacy 
(13). Evidence from Sub-Saharan Africa suggests that HIV-infected pregnant women have lower rates of 
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retention in care (a precursor to ART adherence) than non-pregnant women and men (14,15).  
Moreover, ART adherence is strongly associated with reaching viral suppression (16,17) while non-
adherence is associated with viremia (VL>1000copies/mL) – the driving force behind MTCT (18).  
With the influx of pregnant and postpartum women initiating ART (8), their low retention rates (14,15) 
and the high rate of adherence necessary to maintain viral suppression (13), HIV-infected pregnant and 
postpartum women have become the focus of much research (8). Several studies have investigated 
maternal HIV-related health outcomes and their possible determinants (19). One such determinant, 
gaining attention in recent years, is knowledge (19). This topic forms the basis of the following review.     
OBJECTIVE 
The main objective of this literature review is to review and evaluate previous work which has examined 
associations between HIV, ART, and MTCT/PMTCT knowledge and maternal HIV-related health 
outcomes in Sub-Saharan Africa. 
SEARCH STRATEGY  
The PubMed databases hosted by the National Centre for Biotechnology Information (NCBI) were 
searched using the following two sets of search terms: “(HIV OR MTCT OR ART) AND (pregnancy OR 
postpartum) AND knowledge AND Sub-Saharan Africa” and ”(adherence OR retention OR viremia) AND 
option B+ AND Sub-Saharan Africa”.  Titles and abstracts of the resultant literature were reviewed to 
select core articles. Reference lists of these articles were reviewed to obtain additional relevant articles. 
Where appropriate, reference lists of these additional articles were used to acquire further literature.  
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SUMMARY OF THE LITERATURE 
Retention, adherence and viral control among pregnant & postpartum women 
initiating ART under Option B+ in Sub-Saharan Africa 
Option B+ is potentially far superior to its preceding strategies due to its non-discriminatory and 
permanent nature (9). Since it is a universal strategy, there is no need for CD4 count measures or any 
additional assessment of disease progression or gestational age (20,21). In resource limited settings, it is 
generally considered simpler to implement which has a major impact on regions of Sub-Saharan Africa 
where HIV is considered to be a generalized epidemic (20–22).   
Nonetheless, implementation of Option B+ is not without challenges. To fully benefit, women often  
initiating ART when healthy, must remain in care and on treatment for the rest of their lives (8). 
Consequently, evidence suggests that retention and engagement in ART services is imperfect (3,8,23–
28). A number of studies have investigated retention in care and/or loss to follow-up (LTFU) as well as 
adherence to ART following Option B+ implementation (3,8,23–28).  Evaluation of these outcomes 
depends on the definitions used and difficulty arises due to the close relationship between retention, 
which is generally regarded as a precursor to adherence, and adherence (8). As with many pragmatic 
measures carried out in resource limited settings, obtaining accurate estimates can depend on the study 
resources. For example, women may be incorrectly identified as LTFU when they could simply be 
receiving care at another facility (8).  Problems also arise when retention is used as a proxy for 
adherence since a women may be adherent if receiving care elsewhere, although defined as not 
retained (8). While these issues should be noted, the umbrella term ‘engagement in ART services’ has 
been suggested to encompass retention in care and adherence following which, viral control can be 




Since the introduction of Option B+, studies from Malawi, Cameroon, Mozambique, Zimbabwe and 
Ethiopia have investigated retention and/or LTFU rates (10, 21, 22, 29-32). In a national Malawian study, 
Tenthani et al found that 82% of 21 939 mothers remained in care after six months (29). A further 
analysis including pregnant (n=3320) and  breastfeeding (n=2037) women as well as women initiating 
ART for their own health (n=6177) found six month retention rates of 70.6%, 83.9% and 90.4%, 
respectively (29). A later Malawian study, including much the same cohort, noted 12, 24 and 36 month 
retention rates of 76.8% , 70.8% , 69.7%, respectively (30). In an urban based Cameroon cohort of 
pregnant and breastfeeding women (n=268),  Atanga et al found six month retention rates of 88.0% 
reducing to 81.1% at 12 months, 74.2% at 18 months and 73.3% after 24 months (10). In Ethiopia, Mitiku 
et al found retention in care to be 88.1% at six months, 84.3% at 12 months and 77.4% at 24 months, 
among 346 pregnant and breastfeeding women in an urban setting (31). 
Rural cohorts in Mozambique and Zimbabwe had worse rates of retention although comparability with 
urban cohorts is problematic due to different health systems and practices. In Mozambique Llenas-
Garcia et al found poor 12 month retention rates among pregnant (41.8%) and lactating women (40.4%) 
(n=308) (21).Similarly Erlwanger et al found 12 month retention rates of 67.7% among a large 
Zimbabwean cohort (n=1113) of pregnant women (32). A much smaller study (n=157) in Zimbabwe 
estimated a six month retention rate of 83% among pregnant and breastfeeding women (22). 
Overall, findings indicate that six month retention, where estimated, is fairly high and similar across 
study settings, ranging from 82% to 88%. Twelve month retention rates were far more variable, ranging 
from 40% to 84%. This is largely due to very low retention rates in Mozambique (21). If data from 
Mozambique are excluded, a narrower range is observed (68% - 84%). Two year retention rates were 
only available for Malawi, Cameroon and Ethiopia and ranged from 71 to 77%. Only a single study 
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considered retention at 36 months which was estimated to be 70% (Malawi) (30). As evidence by these 
studies, retention of pregnant and postpartum women is suboptimal and declines consistently.   
Adherence 
Ugandan and Zimbabwean studies have investigated ART adherence under Option B+ (20,32). In Uganda 
Schnack et al found a median pill count adherence of 95.7% in 124 pregnant women (20). Furthermore 
they noted that 21.1%, 27.6% and 51.3% of women had low (<80%), moderate (80-94.9%) and adequate 
(>95%) adherence rates, respectively (20). In Zimbabwe Erlwanger et al found a one year adherence rate 
of 39.1% in women initiating ART during pregnancy (n=1113) (32).In this study adherence was measured 
by dispensary records and a medication possession ratio (32). In comparison it appears that adequate 
adherence rates were ~10% higher in Uganda. Both studies were conducted in rural settings so perhaps 
discrepancies are the result of inter-country differences or different methodologies. It is difficult to draw 
conclusions on adherence from such limited data; nonetheless, adherence rates appear suboptimal and 
worse than retention rates. 
Viral Control 
Use of and health system capacity to carry out routine VL monitoring is limited in Sub-Saharan Africa (8). 
As such, three of five  identified studies that utilized VL measurements were based in South Africa, with 
one each in Malawi and Rwanda (33–37). In South Africa, viral suppression (VL<50copies/mL) of 574 
pregnant women already on ART was 78% at the time of their first antenatal visit (33). Of the remaining 
22%, 13% had VLs >1000copies/mL and 7% had VLs >10 000copies/mL (33). In a linked study (same clinic 
population), viral suppression among  620 women initiating ART during pregnancy was evaluated (34). 
At delivery, 73% of these women were virally suppressed and a cumulate 91% had VLs <1000 copies/mL, 
posing a minimal MTCT risk (34). Postpartum follow-up of an overlapping cohort indicated that 70% of 
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women sustained viral suppression through 12 months postpartum, 8% of women experienced a minor 
vireamic episode (VL: 50-1000copies/mL) and 22% at least one major vireamic episode 
(VL>1000copies/mL) (35).  
In a large study (n=1269) based in Malawi, 84% of pregnant or breastfeeding women had VLs 
<1000copies/mL six months after treatment initiation (36).  The remaining 16% were considered to have 
virologic failure (36). Among 608 pregnant and postpartum women in Rwanda, most of whom were on 
ART prior to entry into antenatal care, 85% of women had VLs <1000copies/mL during late pregnancy or 
the early postpartum period (37). It was also noted that VL tended to be higher in those who had been 
on ART for more than three years (37). 
The evidence from South Africa indicates that VL increases with increased ART duration throughout the 
gestational and postpartum period (33–35). Given that the studies in Malawi and Rwanda analyzed VL at 
different time points, it is difficult to compare results across the three settings (36,37). Even so, evidence 
suggests that viral control during pregnancy and the postpartum period is suboptimal.  
HIV, ART and PMTCT knowledge among pregnant & postpartum women in Sub-
Saharan Africa 
Lack of knowledge about HIV, ART and/or MTCT/PMTCT has been hypothesized to contribute to poor 
health outcomes (38–46). This is of particular concern in key populations such as women of childbearing 
age and pregnant and postpartum women due to the increased risk of HIV-acquisition during pregnancy 
and the risk of MTCT if HIV-infected (8,47). Nine South African studies evaluating knowledge in these key 




In a small 2013 study of 67 women of childbearing age (22% HIV-infected) in rural South Africa, most 
participants (>90%) were aware of major HIV transmission methods but there were several 
misconceptions surrounding transmission by other means (38). Only 67.2% of participants knew 
progression of HIV to AIDS could be prevented by ART and 35.8% of participants thought HIV could be 
cured (38). Most participants (>90%) knew about MTCT but far fewer were aware that vertical 
transmission could occur during pregnancy (55%), labour/delivery (27%) or breastfeeding (29%) (38).  
Five studies included pregnant women from South Africa (39–43). Between 2006 and 2007, among 160 
women receiving PMTCT services in a peri-urban setting, Futterman et al found that overall knowledge 
was generally reasonable but knowledge on CD4 counts and VL was lacking (39). Three studies including 
the same pregnant women, attending antenatal services in a rural setting, found that women and their 
partners (n=478)  possessed moderate HIV-related knowledge (40–42). In addition,  when knowledge of 
these participants was evaluated by in-depth interviews, participants were considered to have “some” 
knowledge of HIV and PMTCT (43).   
Among the studies carried out in postpartum women, a 2006 study in rural South Africa (n=202 HIV-
infected) found high levels of HIV transmission (98%) and prevention (94%) knowledge (44). As with 
other groups, PMTCT knowledge was poor with only 56% and 73% of participants assessed to have 
appropriate knowledge on vertical transmission and its prevention, respectively (44). A larger study in 
2008  (n=815), among mothers in a PMTCT programme in rural South Africa,  found that only 71% of 
participants were aware of MTCT (45). Furthermore, while 54% of participants were aware that MTCT 
occurs sometimes, over 30% thought that MTCT always occurs between an HIV-infected mother and her 
infant (45). A qualitative study has provided additional insight on postpartum women’s HIV/ART 
knowledge (42).   A 2016 study of 15 postpartum mothers receiving  PMTCT services revealed that most 
participants knew that a mother could infect her infant at various stages but were not sure how and did 
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not understand how transmission after birth occurs. These participants were however aware that 
prevention methods for MTCT existed and that adhering to ART was critical for PMTCT (42).   
Work from other Sub-Saharan African countries supports the findings from South Africa. In rural 
Mozambique, only 56% of 27 HIV-related questions were answered correctly by 348 women receiving 
antenatal care (48). A study carried out at the same time (2011) in rural Uganda, among a general 
population of women of childbearing age (n=100), found very low rates of knowledge, with 7% having 
adequate MTCT knowledge (49). In 2011 in Ghana, among 229 HIV-infected women of reproductive age, 
90% had inadequate ART and PMTCT knowledge (3). A 2011 study in Cameroon found PMTCT 
knowledge among 477 pregnant women was good overall but this was likely due to HIV and PMTCT talks 
routinely given at the clinic (50). In 2012 national data from Tanzania showed that 45% of HIV-
uninfected (n=9737) and 56% of HIV-infected women (n=562) had adequate knowledge on MTCT and 
PMTCT (51). In 2014 in rural Nigeria, 78% of pregnant women in care (n=450) had adequate knowledge 
on MTCT but only 28% of women knew that ART was a means to prevent  MTCT (52). In rural Ethiopia in 
2014, 63.8% of 542 pregnant women, some of whom were in care, had appropriate knowledge of HIV 
while 19% had comprehensive MTCT knowledge (53).  
Overall, this research indicates that HIV, ART and MTCT/PMTCT knowledge among both women of 
childbearing age and pregnant and postpartum women is imperfect. In particular, knowledge of vertical 
transmission seems to be poor. Although difficult to assess from the available literature, there is some 
evidence that knowledge is improving as scale-up in ART services takes place and that knowledge of 
MTCT is better among women who are pregnant or breastfeeding than the general population. It is also 
worth noting that the majority of the published findings have occurred in rural populations. As such, 
they may not generalize, especially to urban populations who typically have more consistent access to 
healthcare and information about healthcare. 
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Mechanisms through which knowledge may impact ART outcomes 
A lack of knowledge may act as a substantial barrier to accessing healthcare, remaining in healthcare 
and adhering to medication. However, enhancing knowledge is considered one of the easiest 
interventions to evoke behavioural change and the identified gaps in knowledge may represent an 
opportunity for meaningful interventions (54,55). Social-cognitive theory suggests that improving 
knowledge can lead to behaviour change and the applied focus is on social-cognitive methods that lead 
to health promotion and disease prevention (55). The theory identifies health determinants, their 
mechanisms and best methods for translating knowledge into action (55). Determinants typically 
include: (i) knowledge about health risks and practices, (ii) self-efficacy, (iii) expected outcomes, (iv) 
personal goals and (v) barriers to and facilitators of change (55). Analyzing this theory in its entirety is 
beyond the scope of this review but it is important to note that knowledge is at the forefront and can be 
considered a prerequisite for behaviour change to occur (55).  
Improvement to knowledge has typically been approached through various formal and informal 
educational interventions (55). Moreover, education has long been considered an important component 
of HIV-programmes (56). A theoretical model of health education, known as the knowledge-attitude-
behaviour/practice (KAB/P) model, has been developed (57). In the KAB/P model, knowledge is defined 
as gaining information, by means of education or experiences, which can be retained and utilized to 
make decisions (58). Attitude is a psychological construct and is denoted by having favourable or 
unfavourable feelings towards something (58). Finally, practice refers to health-related behaviours 
which lead to disease aversion or delayed progression of disease (58). This model postulates that 
behaviour and practice can be directly influenced by both knowledge and attitudes (59). It further 
suggests that knowledge acquisition and attitude modulation are gradual and accumulative, potentially 
leading to long-term behaviour modification as they become a motivational driver for change (59). The 
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relationship between these three constructs is not straight-forward but dynamic and multidirectional 
(60). Knowledge may inform an individual’s attitude and  these feelings may alter behaviour  but the 
converse is also possible (60). Behaviours may influence attitudes which then influence perceptions and 
potentially the amount of knowledge acquired (60).   
Associations between HIV, ART and/or MTCT/PMTCT knowledge and HIV-related 
health outcomes in Sub-Saharan Africa 
The literature search identified 11 studies investigating the relationship between HIV, ART and/or 
MTCT/PMTCT knowledge and HIV-related health outcomes (Table B1). Three studies explored retention 
in care or defaulting from care, four studies explored medication adherence and individual studies 
considered access to ART, uptake of ARVs, use of antenatal care and PMTCT and transmission risk 
behaviours. No studies investigated HIV VL as a clinical outcome.  
Retention in Care/Defaulting 
Of the three studies investigating this outcome, two found significant associations (3, 25). In Ghana, 
women with inadequate ART/PMTCT knowledge had a significantly higher risk of defaulting compared to 
those with adequate knowledge (OR=3.5, 95% CI:1.89-6.21) (3). This study included 206 HIV-infected 
women of reproductive age, measured knowledge by a questionnaire and classified defaulting as 
missing at least two consecutive ART appointments (3). In Malawi, high ART knowledge scores were 
associated with an increased odds of retention in care (OR=1.60, 95% CI:1.15-2.23, P=0.004) among 
women on ART, 82% of which were pregnant (25). Knowledge was measured by a questionnaire,  cases 
(n=50) were individuals out of ART for more than 60 days and controls (n=153) were individuals 
remaining in care for at least 12 months (25).  In Uganda, no discrepancies between knowledge among 
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those in care and ART defaulters were noted (23).  This qualitative study included 45 HIV-infected 
pregnant women and measured knowledge by in-depth interviews (23). 
General limitations of these studies included self-reported measures vulnerable to recall bias and social 
desirability bias (answering questions to conform to norms (23)) as well as potential questionnaire 
limitations. Questionnaires may hinder the ability to comprehensively test knowledge since closed-
ended questions allow participants to recognize correct answers. This may ultimately lead to 
measurement of passive knowledge rather that active knowledge that could influence behaviour (3). In 
Ghana specifically, few women had adequate knowledge (n=17), the cross-sectional nature makes it 
impossible to ascertain whether knowledge preceded non-defaulting and ART counseling across facilities 
was not accounted for (3). In Malawi there were low numbers of defaulters (n=50) and no corrections 
for multiple testing (25). In Uganda the study was small and qualitative in nature (23).   
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Table B 1: Summary of knowledge and HIV-related health outcome associations in Sub-Saharan Africa.  











Outcome Main finding 
Duff et al 
(23) 




In-depth interviews & 
focus groups 













ART & PMTCT Retention/ 
defaulting 
Defaulting rate significantly higher 
in those with inadequate 
knowledge compared to those with 
adequate knowledge  
Hoffman  
et al (25) 
Malawi 2014-
2015 
203 HIV+ women 
initiated on ART  
Yes Case-control Questionnaire ART, PMTCT Retention/ 
defaulting 
Knowledge scores significantly 
higher among non-defaulters 






215 HIV+ mothers 




Questionnaire & scores MTCT Adherence  Increased MTCT knowledge 
associated with increased maternal 
adherence 









Questionnaire & scores MTCT Adherence No association 
Ekama  et 
al (28) 





classification as good or 
poor 
HIV, ART Adherence No association 
Ebuy  et al 
(24) 





classification into high, 
moderate low  
HIV, ART, 
PMTCT 
Adherence No association 
Kohler  et 
al (61) 





Questionnaire & scores HIV, PMTCT ARV uptake HIV prevention knowledge and 
PMTCT knowledge associated with 
increased uptake of ARVs 
Muchedzi 
et al (61) 






classification as  <50 or 
>50 
PMTCT Access to 
care 
No association 
Sahlu  et al 
(63) 
Ethiopia 2011 7392 
 







classification into high 
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Only one of four studies identified a significant knowledge-adherence association (45). In South Africa, 
Peltzer et al found MTCT knowledge to be associated with increased adherence to  nevirapine (an ARV) 
for PMTCT (OR=1.67, 95% CI:1.28-1.68, P<0.001) (45). This study included 815 HIV-infected mothers, 
measured knowledge and ART adherence by questionnaires and defined non-adherence as not taking 
nevirapine as prescribed or not at all (45).  
Studies that found no association included a later South African study (Peltzer et al), a Nigerian study 
(Ekama et al) and an Ethiopian study (Ebuy et al) (24,27,28). Peltzer et al examined factors associated 
with adherence to nevirapine and AZT (ARVs) among HIV-infected antenatal (n=139) and postnatal 
women (n=607) (27). They measured knowledge by a questionnaire and adherence by self-report where 
non-adherence to nevirapine was defined as not taking it as prescribed or not at all while adherence to 
AZT was defined as never missing a dose (27). Ekama et al examined determinants of adherence in 170 
pregnant women accessing PMTCT services (28). ART knowledge was classified as ‘good’ or ‘not good’ 
based on questionnaire scores greater or less than 70%, respectively. Adherence was measured using 
the percentage of doses taken based on three day recall and rates ≥95% were considered good (28). 
Ebuy et al investigated factors associated with adherence to Option B+ among 277 women (24). They 
measured PMTCT and ARV knowledge as well as adherence by questionnaires (24). Knowledge was 
classified as low, moderate or high while adherence was classified as good or poor (24). All four of these 
studies were limited by the use of self-report to measure adherence and potentially minor issues 
surrounding the use of questionnaires. Peltzer’s studies were further limited by not randomly selecting 
participants, hindering generalizability (27, 45).   
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Uptake of ARVs, Access to ART & Use of Antenatal care 
An association was only found between knowledge and ARV uptake (61). In Kenya, Kohler et al found 
that increased knowledge was associated with increased ARV uptake among 247 HIV-infected mothers 
(61). Knowledge was assessed and scored by a questionnaire and HIV status and ARV uptake were 
measured by self-report (61). In Zimbabwe, Muchedzi et al found no association between PMTCT 
knowledge and access to care (62). They included 147 women in PMTCT programmes with referral to 
ART services, measured and  categorized knowledge  (>51% or <51%) using a questionnaire and defined 
access to care as successful registration at a referral clinic (62). In Ethiopia, Sahlu et al found no 
association between HIV or MTCT knowledge and the use of antenatal care among 7392 HIV-infected 
women who had given birth in the previous five years (63). MTCT knowledge was measured using a 
questionnaire and classified as high or low if women answered all questions correctly or not. Antenatal 
care was measured by self-report (63).  
In general, these studies were limited by their cross-sectional nature and possibly social desirability bias. 
More specifically, the Kenyan study was limited by self-reported measures (61), the Zimbabwean study 
was limited by the sample size and LTFU (23%) (62) and the Ethiopian study was limited by self-report 
and not accounting for different types and qualities of antenatal care (63).   
PMTCT-related and Transmission Risk Behaviours 
In addition to PMTCT-related behaviours, transmission risk behaviors which may include a lack of 
condom use, no knowledge of sexual partners’ HIV status or having multiple sexual partners, is of special 
concern. This is because hormonal changes make pregnant women especially vulnerable to HIV-
infection and because of the incidental implications of perinatal infections (39,47,64).  In South Africa, 
Futterman et al found no association between general HIV knowledge and PMTCT and transmission 
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behaviours (39). This  small intervention study included 160 HIV-infected pregnant women at two 
maternity clinics where the intervention arm included additional peer-support and learning sessions 
aimed at improving health (39). The intervention significantly increased knowledge scores six months 
post-delivery (among the 44% retained) as measured by a questionnaire (39). PMTCT and transmission 
behaviours between the two groups, however, did not differ (39). This study was not randomized, LTFU 
rates were high and measurements were based on self-report so findings may reflect aspects of bias in 
the resulting sample.  
Summary  
 The evidence is inconclusive with respect to knowledge-retention and knowledge-adherence 
associations. While some studies found positive associations (3,25,45), others failed to demonstrate an 
association (23,24,27,28). The variation in findings could be due to the utilization of different 
methodologies, different study settings or individual study limitations, particularly the use of cross-
sectional data. Evidence from single studies investigating other health outcomes, is insufficient to draw 
any valid conclusions (39, 61–63).  Furthermore, with very few studies investigating knowledge as a 
potential factor in clinical outcomes and none evaluating HIV VL, conclusions cannot be drawn about the 
impact of knowledge on clinically measurable health outcomes. This lack highlights the need for further 
research that specifically interrogates the potential association between knowledge and viral control. 
While VL is not an explicit measure of ART adherence it is the primary clinical biomarker of ART-related 
outcomes (e.g. adherence) and HIV disease progression (8,12).Moreover, in pregnant and breastfeeding 
women who are at risk of HIV transmission to infants, VL is the chief determinant of that risk (8,35).  
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CONCLUSION & FUTURE DIRECTIONS  
Option B+ lifelong ART for all HIV-infected pregnant and postpartum women has dramatically increased 
the number of women in ART and PMTCT services, reducing the rate of MTCT and improving health 
outcomes (8). While provision of ART in pregnancy and breastfeeding periods has a theoretical potential 
to nearly eliminate new pediatric HIV-infections, this can only become a reality if women remain 
engaged in care and achieve sustained viral suppression (13,65).  This review highlights that retention in 
care, adherence and viral control in women initiating ART, under Option B+, in Sub-Saharan Africa is 
suboptimal. This review revealed gaps in HIV-related, ART and particularly MTCT/PMTCT knowledge 
among women of childbearing age as well as pregnant and postpartum women in Sub-Saharan Africa. 
This lack of knowledge may be a potential driver of the observed suboptimal outcomes. 
In Sub-Saharan Africa poor knowledge has been investigated as a determinant of retention in care, 
adherence, ART uptake, access to ART, use of antenatal care and PMTCT/transmission risk behaviour but 
the results as yet cannot yield any definite conclusions. Unraveling the association between knowledge 
and HIV-related health outcomes is of importance since it can inform interventions to improve maternal 
health. In general, further research on knowledge and HIV-related health outcomes is warranted. More 
importantly, a major research gap is the absence of data on the relationship between knowledge and 
maternal VL outcomes. VL is the key outcome influenced by ART and the main driver of MTCT (8,35). It 
has also been proposed as the gold standard measure for evaluating ART (8), thus an analysis of this 
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ABSTRACT  1 
Introduction: HIV infection during pregnancy and breastfeeding can result in mother-to-child 2 
transmission (MTCT) of HIV if viral load (VL) is not well controlled. In South Africa, where almost one 3 
third of pregnant women are HIV-infected, this is a major concern. Maternal lifelong antiretroviral 4 
therapy (ART) is reducing new pediatric infections by controlling VL but to ensure clinical efficacy 5 
adherence must be extremely high. Empirical evidence shows that ART adherence in pregnant and 6 
breastfeeding women is suboptimal. HIV and ART knowledge among these women is also lacking, 7 
potentially driving suboptimal adherence and subsequent poor viral control. To better understand this, 8 
we investigated the association between knowledge and maternal ART adherence as evaluated by 9 
vireamia (VL>1000 copies/mL).   10 
Methods: We followed a cohort of 376 HIV-infected pregnant women from their first antenatal visit 11 
until 12 months postpartum. HIV and ART knowledge were assessed at three time points by separate 12 
knowledge inventories categorized into general and prevention of MTCT (PMTCT) knowledge. An 13 
overall, general and PMTCT knowledge score was calculated from each inventory. HIV VL at delivery and 14 
at 12 months postpartum was measured and demographic characteristics were surveyed. Univariable 15 
and multivariable regression models were used to assess potential demographic/clinical knowledge 16 
predictors and to estimate the associations between knowledge scores and vireamia.  17 
Results:  Participants were Black African women. Almost half had prior HIV diagnoses (44.7%) and 4.3% 18 
had previously received ART. HIV and ART knowledge increased slightly over the study period. General 19 
knowledge about HIV and ART was typically good while knowledge about PMTCT was lacking. Previous 20 
HIV diagnoses (OR=-0.36;95% CI=-0.09-0.63;P=0.009), weeks on ART at delivery (OR=-0.03;95% CI=0.00-21 
0.06;P=0.047) and level of education (OR=-0.52;95% CI=-0.83- -0.21;P=0.001) were statistically 22 
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significant predictors of HIV knowledge outcomes after adjusting for demographic/clinical variables. 23 
Associations between knowledge scores and vireamia at delivery and 12 months postpartum were 24 
mixed and generally not statistically significant. 25 
Conclusion: General knowledge was good while knowledge specific to PMTCT was comparatively poor. 26 
Timing of HIV diagnoses, time on ART and education were identified as potential predictors of HIV-27 
related knowledge. Neither HIV nor ART knowledge was meaningfully associated with vireamia or 28 
adherence at delivery or at 12 months postpartum.   29 
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INTRODUCTION   30 
Mother-to-child transmission (MTCT) of HIV accounts for 90% of new pediatric infections and can occur 31 
during pregnancy, labour, delivery or breastfeeding when viral load (VL) is not suppressed (1,2).  32 
Prevention of MTCT (PMTCT) interventions are thus aimed at sustaining viral suppression through the 33 
use of antiretroviral therapy (ART) (3). In South Africa, where approximately 28% of pregnant women 34 
are HIV-infected (4), the World Health Organization’s (WHO) Option B+ ART strategy for PMTCT has 35 
been implemented (3). Option B+ endorses initiation of lifelong ART for all pregnant and breastfeeding 36 
women regardless of clinical disease stage, gestational age or CD4 count (5). This has consequently 37 
resulted in an increase of pregnant and postpartum women entering into ART services for the first time 38 
(3). While Option B+ has the potential to transform MTCT rates, its success depends on optimal ART 39 
adherence (≥95%) (6). Empirical evidence has demonstrated that women who initiate ART during 40 
pregnancy in Sub-Saharan Africa, do not remain engaged in ART services (7–19). This can include being 41 
lost from care or not adhering to medication, resulting in uncontrolled VLs and increased risk of MTCT 42 
(3).  43 
Researchers have postulated that a lack of knowledge may in part, be responsible for these suboptimal 44 
HIV-related health outcomes (20). There has been debate as to whether knowledge influences health 45 
outcomes such as adherence, particularly in Sub-Saharan Africa. The knowledge-attitude-46 
behaviour/practice (KAB/P) model best explains the mechanism through which this might occur (21). 47 
Knowledge may result in attitude changes which can act as a motivational driver, ultimately leading to 48 
behavioural changes (21). It is quite possible that women with poor HIV/ART knowledge have negative 49 
or neutral attitudes towards health-improving behaviour and lack the motivation to remain engaged in 50 
ART services.   51 
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A limited number of studies in Sub-Saharan Africa have investigated knowledge and maternal HIV-52 
related health outcomes with inconclusive findings (22–30).  In Ghana, Malawi and Uganda, studies have 53 
been undertaken to assess the relationship between knowledge and retention in care but yielded mixed 54 
results (22–24). Increased knowledge was found to be associated with improved maternal ART 55 
adherence in South Africa but subsequent studies on this association in South Africa, Ethiopia and 56 
Nigeria did not support the conclusions (25–27). Increased knowledge has been associated with 57 
improved ARV uptake in Kenya (31) but not with access to care in Zimbabwe (28), the use of antenatal 58 
care in Ethiopia (29) nor PMTCT and transmission risk behaviours in South Africa (30).  Many of these 59 
studies had several limitations and comparability is difficult due to the lack of standardized 60 
methodology, highlighting the need for further research. 61 
Data on the association between knowledge and VL or any similar clinical outcome in Sub-Saharan Africa 62 
are scarce. This is surprising since VL is the primary measure of successful ART adherence and long term 63 
health in HIV-infected persons (3). VL is also the key driver of vertical transmission where high VL is 64 
associated with an increased risk of transmission in a dose-response manner (3). On this basis, VL has 65 
been proposed as the gold-standard for evaluating ART-related outcomes (3).Given the conflicting 66 
evidence and lack of data, we investigated how the knowledge of HIV-infected pregnant and postpartum 67 
women may be associated with their ART adherence as evaluated by HIV vireamia (VL>1000 copies/mL).  68 
METHODS  69 
This is a sub-study of the Maternal & Child Health Antiretroviral Therapy (MCH-ART) study (32). MCH-70 
ART is a 3 phase implementation science study with the aim of optimizing ART services for pregnant and 71 
postpartum women and their infants (ClinicalTrials.gov NCT01933477). Phase 1 was a cross-sectional 72 
study of consecutive HIV-infected pregnant women attending their first antenatal visit (n=1554). Phase 2 73 
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was an observational cohort study including women from phase 1, initiating ART (n=628). Phase 3 was a 74 
randomized trial to assess two methods of ART delivery during the postpartum period (n=471). MCH-75 
ART was conducted at the Gugulethu Midwife Obstetric Unit (MOU) within the Gugulethu Community 76 
Health Centre (CHC) in Cape Town, South Africa. This is a primary healthcare facility in a peri-urban 77 
setting with antenatal care (ANC) coverage exceeding 95%. The study has been described previously by 78 
Myer et al (32). 79 
Participants  80 
Participants included in the reported results were recruited and followed as part of the MCH-ART study. 81 
This analysis is restricted to participants who were retained throughout the MCH-ART study period and 82 
completed all three study phases. Moreover, analyses were further restricted to participants for which 83 
all knowledge-related data were available (n=376) (Supplementary Figure D1). Recruitment and follow-84 
up occurred between April 2013 and November 2015. Between April and June 2013 women were ART 85 
eligible if their clinical disease stage was III/IV or if they had CD4 counts that did not exceed 350cells/mL, 86 
according to South African national guidelines at the time.  For the remainder of the study period all 87 
women initiated ART irrespective of disease stage or CD4 count as per WHO’s Option B+ strategy, which 88 
was adopted by South Africa in July 2013. The ART regimen consisted of a fixed dose combination of 89 
tenofovir 300mg, emtracitabine 300mg and efavirenz 600mg, once daily. All ART initiation and follow-up 90 
occurred as part of routine care.   91 
All participants signed written informed consent in accordance with the declaration of Helsinki. MCH-92 
ART ethical approval was granted by the Human Research Ethics Committee of the Faculty of Health 93 
Sciences within the University of Cape Town (HREC: 451/2012) and the Columbia University Medical 94 
Centre Institutional Review Board. In addition, the current study obtained ethical approval from the 95 
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Human Research Ethics Committee of the Faculty of Health Sciences within the University of Cape Town 96 
(HREC: 707/2017). 97 
Study Measurements  98 
All data collection took place as part of MCH-ART study measurement visits, carried out separately from 99 
routine care. In total, a maximum of nine study measurement visits were attended by each participant. 100 
These included: two antenatal visits, a visit in the third trimester, a visit within seven days postpartum as 101 
well as visits at 6 weeks, 3 months, 6 months, 9 months and 12 months postpartum. Window periods up 102 
until the midpoint of the prior or following visit were allowed for participants who arrived before or 103 
after expected visit dates. Various study measurements were collected during these visits, subsets of 104 
which were included in this research (32).  105 
HIV-related knowledge was assessed by an eight item inventory while ART-related knowledge was 106 
assessed by a nine item inventory. The timing of knowledge assessments and number of participants 107 
completing each is indicated in Supplementary Figure D1.  Each inventory was subdivided into general 108 
knowledge items and PMTCT knowledge items. Scores for each inventory and subcategory were then 109 
calculated by the sum of correct responses, leading to six knowledge scores per knowledge assessment 110 
visit. Inventories were administered by trained interviewers in participants’ home language (isiXhosa). 111 
HIV VL at delivery and at 12 months postpartum was assessed via blood tests performed on 5mL of 112 
venous blood which was collected from each participant into serum separating tubes. Batched VL testing 113 
was conducted using the Abbott Molecular RealTime HIV-1 assay (Abbott Molecular, Illinois, USA).  VL 114 
measures below the lower detectable limit were recorded as 39copies/mL.  Blood draws were 115 
performed by trained phlebotomists and VL testing was performed by trained individuals. Participant 116 
demographic characteristics and medical history were assessed by a questionnaire. This was 117 
administered in isiXhosa by trained interviewers at the second antenatal visit.  118 
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Statistical Analyses 119 
Participant descriptive summaries were by medians and interquartile ranges (IQR) or by frequencies (%) 120 
as well as χ2 tests for comparisons. HIV and ART knowledge was summarized by frequencies of item-121 
specific correct answers and inventory scores, mean scores and cumulative number correct. The internal 122 
consistency of the knowledge inventory scales was assessed using Cronbach’s alpha (α).  Univariable and 123 
multivariable linear regression models were used to estimate associations of demographic/clinical 124 
variables with knowledge scores at the first knowledge assessment. Covariates for inclusion in 125 
multivariable models were selected a priori.  Univariable and multivariable logistic regression models 126 
were used to estimate associations between vireamia at delivery and 12 months postpartum and 127 
knowledge scores at the first knowledge assessment. Sensitivity analyses were conducted to estimate 128 
these associations after excluding women with very poor knowledge. Coefficients, odds ratios and 95% 129 
confidence intervals are reported. Data was analyzed using STATA V14.0 (Stata Corporation, College 130 
Station, Texas, USA) and statistical significance was set at α=0.05 for all analyses.    131 
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RESULTS  132 
Participant Characteristics  133 
Participant characteristics are summarized in Table C1. A total of 471 participants completed every 134 
phase of the MCH-ART study. Of these, 376 participants completed all three knowledge assessments 135 
and are included in the analyses. Demographics were similar between those who completed every MCH-136 
ART phase and the subset that completed all knowledge assessments (Table C1). All participants were 137 
Black African women; most had less than a secondary level education (75.5%) and most were 138 
unemployed (60.9%). Participants were generally evenly distributed between socioeconomic status 139 
(SES) categories (low: 26.6%, moderate: 34.8%, high: 38.6%) and poverty categories (least 140 
disadvantaged: 33.5%, moderately disadvantaged: 33.5%, most disadvantaged: 33.0%). Most 141 
participants were multiparous (84.6%) and the majority of pregnancies were unplanned (70.2%). 142 
Approximately half the participants had been previously diagnosed with HIV (44.7%) but only 4.3% had 143 
previously received ART. At study enrolment, 85.1% of participants had elevated VLs (median: 9907.0; 144 
IQR: 2539.0-36494.5 copies/mL). At the time of delivery, this percentage was 6.4% (median: 39.0; IQR: 145 
39.0-48.0 copies/mL) but increased to 32.2% at 12 months postpartum (median: 39.0; IQR: 39.0-680.0 146 
copies/mL).  147 
In a comparison between the subset of women who experienced vireamia at 12 months postpartum (n= 148 
88, 23%) and the study population as a whole (Supplementary Table D1), variables that appeared 149 
appreciably different were: employment, nature of pregnancy, relationship status and VL at enrolment. 150 
Those with vireamia at 12 months postpartum were more likely to be unemployed, not 151 
married/cohabitating, have unintended pregnancies and experience vireamia at enrolment compared to 152 
those without vireamia at 12 months postpartum.  153 
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Table C 1: Descriptive characteristics of HIV-infected pregnant women completing all three phases of 154 
MCH-ART and the subset who completed all knowledge assessments.  155 
Variable Median (IQR) or n (%)  
 All 3 phases of MCH-ART (n=471) All knowledge assessments (n=376) P-value 
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† VLs below the lower detectable limit were set at 39copies/mL 
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HIV & ART Knowledge  156 
All HIV (Cronbach’s alpha (α): 0.39) and ART (Cronbach’s alpha (α): 0.53) knowledge inventory items are 157 
described in Table C2.HIV general knowledge slightly increased over time (% achieving max score: 64 to 158 
73%). HIV PMTCT knowledge also increased over time (% achieving max score: 2 to 4%). HIV general 159 
knowledge was typically better than HIV PMTCT knowledge as shown by frequencies of those obtaining 160 
maximum scores for each subcategory (Figure C1 a-c). The overall mean scores for HIV knowledge were 161 
similar across assessments (Table C2). The mean HIV general knowledge score increased over time by 162 
less than a single point. The mean HIV PMTCT score decreased at six weeks postpartum and then 163 
improved both by less than a single point. Supplementary Figure D2 (a-c) shows item-specific 164 
frequencies of correct answers for HIV knowledge over time. Over the study period, items that were 165 
poorly answered were 7, 8 and 9 which all related to PMTCT knowledge.   166 
ART general knowledge improved over time as the frequency of individuals answering five or six 167 
questions (maximum score) correctly increased (Figure C1 d-f). ART PMTCT knowledge also increased 168 
over time as the frequency of individuals answering two (maximum score) questions correctly increased 169 
(Figure C1 d-f). ART PMTCT knowledge was better than ART general knowledge, in contrast to the HIV 170 
general/PMTCT findings. These findings were confirmed by mean scores over the study period (Table 171 
C2). Overall mean scores for ART knowledge increased over time (second antenatal visit: 6.5; 6 weeks 172 
postpartum: 7.0; 9 months postpartum: 7.2), driven by ART general knowledge (second antenatal visit: 173 
4.6; 6 weeks postpartum: 5.0; 9 months postpartum: 5.3). Supplementary Figure D2 (d-f) illustrates 174 
item-specific frequencies of correct answers for ART knowledge items over the study period. Item 8, 175 
which concerned transmission knowledge, was consistently poorly answered. Generally, ART knowledge 176 
appeared better than HIV knowledge.   177 
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Table C 2: HIV and ART knowledge mean scores and item-specific frequencies of correct answers at the three knowledge assessments.  178 
179 80

























Is HIV/AIDS spread by kissing? 
Must a person have many different partners to get HIV/AIDS? 
Is HIV the virus that causes AIDS? 
Is there a cure for HIV/AIDS? 
Mean number correct 
PMTCT 
Can a pregnant woman give HIV/AIDS to her baby? 
Are there medications that a woman can take to protect her baby from getting HIV/AIDS? 
Can a woman give HIV/AIDS to her baby during breastfeeding? 
Does formula feeding reduce the risk of a baby getting HIV? 
Do caesarian sections reduce the risk of a baby getting HIV? 

























































ART knowledge  
General 
Antiretroviral medication aims to reduce or suppress the activity of the HIV virus in the body. 
Taking antiretroviral medications on schedule helps keep the right amount of medicine in one’s system. 
Viral load measures the amount of HIV virus in the blood. 
Sometimes lab results say that a person’s viral load is “undetectable.” This means that there is no virus left. 
Taking antiretroviral therapy exactly as prescribed is likely to reduce viral load. 
If a person takes antiretroviral therapy and has a low viral load, they may be less likely to transmit the virus 
through having sex with an HIV-negative partner. 
Mean number correct 
PMTCT 
Taking antiretroviral therapy can reduce a child's risk of becoming HIV infected during pregnancy and delivery. 
Taking antiretroviral therapy can reduce a child's risk of becoming HIV infected during breastfeeding. 















































Figure C 1: Frequencies of HIV knowledge scores (a-c) and ART knowledge scores (d-f) at the second antenatal visit, 6 weeks postpartum and 9 
months postpartum. White bars pertain to HIV general knowledge, black and white checked bars pertain to HIV PMTCT knowledge, grey bars 
pertain to ART general knowledge and grey and black checked bars pertain to ART PMTCT knowledge. 
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Analysis of Knowledge Predictors 182 
Regarding overall and general HIV knowledge, education, SES and previous HIV diagnosis were all 183 
significant predictors in univariable analyses (Table C3). In multivariable analyses, low education and 184 
previous HIV diagnoses remained significant predictors of improved overall and general HIV knowledge. 185 
In univariable analyses of HIV PMTCT knowledge, SES was a significant predictor (β=-0.25; 95% CI=-0.46 - 186 
-0.03; P=0.023). In multivariable analyses of HIV PMTCT knowledge, the only significant predictor was 187 
weeks on ART at delivery (β=0.03; 95% CI=-0.00 - 0.06; P=0.047). 188 
Regarding ART knowledge, gestational age at enrolment and previous ART use were significant 189 
predictors of overall ART knowledge in univariable analyses (Table C4). Age and timing of ART diagnosis 190 
were marginally significant predictors of ART general knowledge in univariable analyses. Gestational age 191 
at enrolment and time on ART were significant predictors of ART PMTCT knowledge in univariable 192 
analyses.  In multivariable analyses, no variables remained statistically significant with respect to any 193 
ART knowledge outcomes.  194 
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Table C 3: Coefficient estimates, 95% confidence intervals (CI) and P-values for univariable and 195 
multivariable linear regression models of the predictors of HIV knowledge scores.  196 
† Delivery  197 
‡ 12 months postpartum  198 
  HIV Overall HIV General HIV PMTCT 
  β (95% CI)  P-value β (95% CI)  P-value β (95% CI) P-value 
Univariable       


































































































































































Gestational age at enrolment -0.01(-0.03-0.01) 0.216 0.00(-0.01-0.01) 0.587 -0.01(-0.02-0.01) 0.223 
Previous HIV diagnosis 0.32(0.06-0.59) 0.017 0.20(0.05-0.35) 0.010 0.13(-0.08-0.33) 0.227 
Previous ART 0.46(-0.20-1.12) 0.173 0.24(-0.13-0.61) 0.195 0.21(-0.29-0.72) 0.407 
Time on ART† 0.00(-0.02-0.02) 0.756 0.00(-0.01-0.01) 0.857 0.00(-0.01-0.02) 0.590 
Time on ART‡ 0.00(-0.020.01) 0.627 0.00(-0.01-0.01) 0.902 0.00(-0.02-0.01) 0.585 
Multivariable       











































Previous HIV diagnosis 0.36(0.09-0.63) 0.009 0.23(0.07-0.38) 0.004 0.14(-0.07-0.34) 0.202 
Time on ART† 0.03(-0.01-0.06) 0.169 0.00(-0.02-0.02) 0.773 0.03(0.00-0.06) 0.047 
Time on ART‡ -0.02(-0.06-0.01) 0.110 0.00(-0.02-0.02) 0.981 -0.02(-0.05-0.00) 0.038 
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Table C 4: Coefficient estimates, 95% confidence intervals (CI) and P-values for univariable and 199 
multivariable linear regression models of the predictors of ART knowledge scores.  200 
† Delivery  201 
‡ 12 months postpartum 202 
  ART overall ART General ART PMTCT 
  β (95% CI)  P-value β (95% CI)  P-value β (95% CI) P-value 
Univariable       


































































































































































Gestational age at enrolment -0.02(-0.03-0.00) 0.037 -0.01(-0.02-0.00) 0.128 -0.01(-0.01-0.023) 0.023 
Previous HIV diagnosis 0.27(0.03-0.51) 0.025 0.20(0.00-0.40) 0.048 0.07(-0.01-0.16) 0.103 
Previous ART -0.02(-0.62-0.57) 0.941 0.12(-0.37-0.61) 0.626 -0.14(-0.36-0.07) 0.189 
Time on ART† 0.01(0.00-0.03) 0.157 0.00(-0.01-0.02) 0.549 0.01(0.00-0.01) 0.011 
Time on ART‡ 0.01(-0.01-0.02) 0.456 0.00(-0.01-0.01) 0.934 0.01(0.00-0.01) 0.062 
Multivariable       











































Previous HIV diagnosis 0.24(-0.01-0.48) 0.061 0.18(-0.03-0.38) 0.092 0.06(-0.03-0.15) 0.192 
Time on ART† 0.02(-0.01-0.06) 0.151 0.02(-0.01-0.04) 0.332 0.01(0.00-0.02) 0.084 
Time on ART‡ -0.01(-0.04-0.02) 0.376 -0.01(-0.03-0.01) 0.414 0.00(-0.01-0.01) 0.567 
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Analysis of Knowledge and Vireamia  203 
Cumulative frequencies of correct HIV and ART knowledge items were similar across VL categories at 204 
delivery (VL<50; VL: 50-1000; VL>1000) (Supplementary Figure D3). This was also true for VL categories 205 
at 12 months postpartum (Supplementary Figure D4).  206 
Figure C2 shows a forest plot of the coefficient estimates and 95% confidence intervals of knowledge 207 
variables in logistic regression models for vireamia outcomes. The majority of estimated associations 208 
were positive, though few were statistically significant. None of the HIV knowledge scores were 209 
significantly associated with vireamia at delivery in any analyses (Table C5). HIV overall knowledge was 210 
significantly associated with vireamia at 12 months postpartum, in adjusted and unadjusted analyses 211 
(OR=1.25; 95% CI=1.04-1.51; P=0.019†, OR=1.30; 95% CI=1.06-1.58; P=0.011‡, OR=1.30; 95% CI=1.06-212 
1.60; P=0.012§ respectively). HIV general knowledge was significantly associated with vireamia at 12 213 
months postpartum, in adjusted analyses only (OR=1.52; 95% CI=1.03-2.25; P=0.034‡, OR=1.53; 95% 214 
CI=1.03-2.28; P=0.037§). HIV PMTCT knowledge was not significantly associated with vireamia at 12 215 
months postpartum in any analyses.  216 
 ART overall and ART PMTCT knowledge were not significantly associated with vireamia at delivery in 217 
adjusted or unadjusted analyses (Table C5). ART general knowledge was significantly associated with 218 
vireamia at delivery when adjusting for demographic variables (OR=1.71; 95% CI=1.03-2.87; P=0.043). 219 
None of the ART knowledge outcomes were significantly associated with vireamia at 12 months 220 
postpartum in any models.  221 
Supplementary Table D2 and Table D3 indicate that most participants, across all VL categories, scored at 222 
least four on the HIV (n=359) and/or ART (n=365) knowledge inventory scales. A sensitivity analysis was 223 
carried out to investigate the knowledge-vireamia associations after excluding women who scored less 224 
than four on these inventories (Supplementary Table D4). All odds ratio estimates decreased in these 225 
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analyses. The only significant positive associations that remained were those for overall HIV knowledge 226 
and vireamia at 12 months postpartum in adjusted analyses (OR=1.27; 95% CI=1.02-1.57; P=0.032‡, 227 
OR=1.26; 95% CI=1.00-1.58; P=0.044§). In addition, ART PMTCT knowledge became negatively associated 228 
with vireamia at 12 months postpartum in adjusted and unadjusted analyses (OR=0.51; 95% CI=0.27-229 
0.98; P=0.045†, OR=0.47; 95% CI=0.24-0.93; P=0.030‡, OR=0.42; 95% CI=0.21-0.87; P=0.019§). 230 
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† Crude 231 
‡ Adjusted for demographic variables (age, education, poverty category) 232 
§
 
Adjusted for demographic and clinical variables (age, education, poverty category, previous ART use, pregnancy 233 
intention, gestational age at enrolment, VL at enrolment, time on ART) 234 
 235 
 236 
Figure C 2: Forest plot of β-coefficient estimates and 95% confidence intervals (CI) for the knowledge 
score variables in unadjusted and adjusted regression models for the outcome variables vireamia 
(VL>1000 copies/mL) at delivery and 12 months postpartum (pp). 
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Table C 5: Odds ratios, 95% Confidence intervals (CI) and P-values for knowledge score variables at the 237 
second antenatal visit in adjusted and unadjusted logistic regression models for the outcome variables 238 
vireamia (VL>1000 copies/mL) at delivery and 12 months postpartum.  239 
† Crude 240 
‡ Adjusted for demographic variables (age, education, SES) 241 
§
 
Adjusted for demographic and clinical variables (age, education, SES, previous ART use, pregnancy intention, 242 
gestational age at enrolment, VL at enrolment, time on ART) 243 
DISCUSSION 244 
Previous studies have estimated associations between HIV, ART and MTCT/PMTCT knowledge and 245 
maternal health outcomes (22–31). None have investigated the relationship between knowledge and 246 
maternal VL – the critical measure of effective ART use and central determinant of MTCT risk (3). In light 247 
of this, we investigated HIV/ART/PMTCT knowledge and vireamia in HIV-infected women initiating ART 248 
during pregnancy. We found that while HIV and ART knowledge increased over time and that there were 249 
significant predictors of knowledge, HIV and ART knowledge were not consistently associated with 250 
maternal vireamia. 251 
During the study period HIV and ART knowledge showed some improvement, with the mean score 252 
increasing by an average of one point. Women had relatively high general knowledge about HIV, for 253 
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example by nine months postpartum more than 80% of participants knew that HIV/AIDS was not spread 254 
by kissing. Women had relatively low HIV PMTCT knowledge, for example by nine months postpartum 255 
only 46.5% of participants knew that a women could transmit HIV via breastfeeding and only 10.4% 256 
were aware that caesarians could reduce MTCT risk. General knowledge about ART was also typically 257 
high. More than 90% of women were knowledgeable on the purpose of ART, the importance of taking 258 
ART as prescribed, and about VLs. Knowledge about transmission was poor, only 39.6% of participants 259 
knew that taking ART and having a low VL could reduce the risk of transmission to sexual partners. These 260 
findings are broadly in line with earlier South African knowledge studies where general HIV/ART 261 
knowledge was acceptable but knowledge on vertical transmission was comparatively poor. Futterman 262 
et al, Jones et al and Griesell et al  all found HIV general knowledge to be reasonable in pregnant or 263 
postpartum women (30,33–36). Similarly, Peltzer et al and Ramoshaba et al found that MTCT knowledge 264 
was generally lacking in HIV-infected postpartum women (37,38).  265 
We identified timing of HIV diagnoses and level of education as predictors of overall and general 266 
knowledge about HIV in adjusted analyses. We also identified duration on ART at delivery as a predictor 267 
of HIV PMTCT knowledge in adjusted analyses. Higher scores were significantly more likely among those 268 
who had previously been diagnosed with HIV and in those with longer durations on ART, suggesting 269 
improved knowledge with longer time in care. Higher scores were also more likely among those who 270 
had not completed any secondary or tertiary education compared to those that had. This association is 271 
contradictory to findings in Mozambique, Tanzania and Ghana which found higher education to be 272 
correlated with better HIV and MTCT/PMTCT knowledge (22,39,40). 273 
For the most part we did not identify any relevant associations between knowledge outcomes and 274 
maternal vireamia. We found similar cumulative frequencies of correct knowledge items across VL 275 
categories, suggesting knowledge did not alter VL. Nonetheless, in some instances we found increased 276 
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knowledge to be associated with worse health outcomes in regression models. Overall and general HIV 277 
knowledge scores were positively associated with vireamia at 12 months postpartum in adjusted 278 
analyses. In addition, ART general knowledge was associated with vireamia at delivery after adjusting for 279 
demographics. Except for the associations between ART knowledge and vireamia at 12 months 280 
postpartum, odds ratios for the knowledge-vireamia associations exceeded one with relatively large 281 
effect sizes, although generally not significant. In sensitivity analyses, when we restricted our sample to 282 
women achieving a score of at least four on the relevant knowledge inventory, the effect sizes were 283 
reduced and in some cases associations were reversed. Nevertheless, some positive relationships 284 
between knowledge and vireamia persisted.  285 
Overall, these findings are counterintuitive and unlikely. Previous work has found positive relationships 286 
between increased HIV, ART or MTCT/PMTCT knowledge and better health outcomes or no evidence of 287 
a relationship. Many of the potential confounders identified in prior research were controlled for in the 288 
current study but some factors such as male partner involvement were not (27). If additional data were 289 
collected, perhaps further analyses adjusting for additional confounders may result in more accurate 290 
estimates of these knowledge-vireamia associations in our study sample.  291 
The major strength of this study is that it investigates the association between HIV and ART knowledge 292 
and maternal vireamia – a research area in which data are sparse. Vireamia is a clinically measurable 293 
outcome unlike many other health outcomes measured by self-report, limiting validity and reliability by 294 
the potential introduction of recall and response bias. This study had limitations in terms of sample size, 295 
methods used to measure knowledge and adherence, possible bias introduced by loss to follow-up, and 296 
generalizability. While the total sample size was relatively large, few participants were noted to have 297 
viremia at delivery (n=24) and at 12 months postpartum (n=88). This may have undermined the power 298 
of the study. Although questionnaires are the most commonly utilized method of knowledge 299 
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assessment, one cannot rule out the possibility that individuals may be able to recognize correct 300 
answers (22). This may overestimate knowledge since recognition does not necessarily translate to 301 
knowledge in practice (22). Moreover, Cronbach’s alpha calculated for the knowledge inventories were 302 
quite low (HIV knowledge: α=0.39; ART knowledge: α=0.53), suggesting potential issues with our scale.  303 
We did not consider maternal attitudes towards HIV, ART and PMTCT which are likely important 304 
intermediates in the KAB/P framework for the influence of knowledge on behaviour. It is also possible 305 
that VL is not a perfect measure of adherence since VL may be influenced by additional factors. Finally, 306 
the study population included HIV-infected women seeking antenatal care at a single primary healthcare 307 
facility in a peri-urban setting in South Africa. Generalization of these results to different settings must 308 
be approached with caution.   309 
As the implementation of lifelong ART for all pregnant and breastfeeding women (Option B+) increases 310 
across Sub-Saharan African countries, more women will initiate ART for the first time (3). Poor ART 311 
adherence will continue to threaten the success of this strategy if barriers to adherence are not 312 
identified and reduced by effective interventions. Improving knowledge is thought to be a straight-313 
forward intervention that can lead to behavioural change and this is likely  relevant in the context of HIV 314 
(41). Pregnant and postpartum women with adequate knowledge may have more favourable attitudes 315 
towards health-seeking and health-promoting behaviour. This could potentially result in increased 316 
motivation to behave in ways culminating in positive health outcomes such as increased ART adherence 317 
and improved viral control. While we did not find evidence that increased knowledge improved 318 
maternal viral control, we did identify gaps in pregnant and postpartum women’s knowledge of HIV 319 




Understanding the association between knowledge and maternal health outcomes can inform 322 
interventions aimed at improving the health of HIV-infected pregnant and postpartum women. This 323 
novel study investigated HIV and ART-related knowledge among women initiating ART during pregnancy 324 
as well as its association with vireamia at delivery and 12 months postpartum. Women’s general HIV and 325 
ART knowledge were high but knowledge on aspects of vertical transmission were lacking. Previous HIV 326 
diagnoses, time on ART and education were identified as possible knowledge predictors. Knowledge was 327 
not meaningfully associated with vireamia, thus it follows that knowledge was not associated with 328 
adherence either. Further investigation of this relationship is required in the current sample as well as in 329 
additional study populations. 330 
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knowledge as well as ART general (c) and PMTCT (d) knowledge stratified by viral load category at 12 360 
months postpartum.  361 
LIST OF ABBREVIATIONS  362 
ANC  Antenatal care 363 
ART   Antiretroviral therapy 364 
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CD4  Cluster of differentiation-4, T lymphocyte 365 
CI   Confidence interval 366 
CHC  Community Health Centre 367 
HIV   Human Immunodeficiency Virus 368 
IQR   Interquartile range 369 
KAB/P  Knowledge-Attitude-Behaviour/Practice 370 
MCH-ART Maternal & Child Health Antiretroviral Therapy Study 371 
MOU   Midwife Obstetric Unit 372 
MTCT   Mother-to-child transmission 373 
NHLS   National Health Laboratory Services 374 
OR   Odds ratio 375 
PMTCT   Prevention of mother-to-child transmission 376 
SES  Socioeconomic status  377 
UCT-HREC  University of Cape Town Human Research Ethics Committee 378 
VL   Viral load 379 
WHO   World Health Organization  380 
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Figure D 1: Design of the current research indicating the timing of knowledge assessments and the 
numbers of participants who completed each (n). 
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Figure D 2: Item-specific frequencies of correct answers for HIV knowledge (a-c) and ART knowledge (d-f) at the second antenatal visit, 6 weeks 
postpartum and 9 months postpartum. White bars indicate HIV general knowledge items, black and white checked bars indicate HIV PMTCT knowledge 




Figure D 3: Cumulative frequencies of correct knowledge items for HIV general (a) and PMTCT (b) knowledge as 
well as ART general (c) and PMTCT (d) knowledge stratified by viral load category at delivery. Red lines indicate 
VL< 50copies/mL, green lines indicate VL: 50-1000 copies/mL and blue lines indicate VL>1000 copies/mL. 
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Supplementary Figure D 4: Cumulative frequencies of correct knowledge items for HIV general (a) and Figure D 4: Cu ulative frequencies of correct knowl dge items for HIV general (a) and PMTCT (b) knowledge as 
well as ART general (c) and PMTCT (d) knowledge stratified by viral load category at 12 months postpartum. 




Table D 1: Descriptive characteristics of all HIV-infected pregnant women included in the study and 
the subset of women with viral loads exceeding 1000 copies/mL at 12 months postpartum. 
 
Variable Median (IQR) or n (%)  
 All women Women with 
VL≥1000 
P-value 
n 376 88  
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 HIV knowledge 
 
0 0(0) 0(0) 0(0) 
1 1(0.4) 0(0) 0(0) 
2 0(0) 1(1.5) 0(0) 
3 11(3.9) 1(1.5) 0(0) 
4 29(10.2) 5(7.5) 3(12.5) 
5 70(24.6) 17(25.4) 3(12.5) 
6 86(30.2) 24(35.8) 7(29.2) 
7 57(20.0) 15(22.4) 9(37.5) 
8 25(8.8) 3(4.5) 2(8.3) 







0 1(0.4) 0(0) 0(0) 
1 1(0.4) 0(0) 0(0) 
2 1(0.4) 2(3.0) 0(0) 
3 5(1.8) 1(1.5) 0(0) 
4 6(2.1) 2(3.0) 0(0) 
5 27(9.5) 7(10.5) 1(4.2) 
6 71(24.9) 10(14.9) 7(29.2) 
7 137(48.1) 34(50.8) 9(37.5) 


























0 0(0) 0(0) 0(0) 
1 1(0.4) 0(0) 0(0) 
2 0(0) 0(0) 1(1.4) 
3 11(4.3) 1(3.3) 0(0) 
4 27(10.6) 2(6.7) 8(9.1) 
5 67(26.3) 5(16.7) 17(19.3) 
6 76(29.8) 13(43.3) 27(30.7) 
7 51(20.0) 7(23.3) 23(26.1) 
8 19(7.5) 2(6.7) 8(9.1) 







0 1(0.4) 0(0) 0(0) 
1 1(0.4) 0(0) 0(0) 
2 1(0.4) 1(3.3) 1(1.1) 
3 5(2.0) 0(0) 1(1.1) 
4 7(2.8) 0(0) 1(1.1) 
5 15(5.9) 4(13.3) 16(18.2) 
6 65(25.5) 8(26.7) 13(14.8) 
7 119(46.7) 15(50.0) 45(51.1) 
8 41(16.1) 2(6.7) 11(12.5) 
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Table D 4: Odds ratios, 95% Confidence intervals (CI) and P-values for knowledge score variables in adjusted 
and unadjusted logistic regression models for the outcome variables vireamia (VL>1000 copies/mL) at 
delivery and 12 months postpartum in the subset of women scoring at least four on the HIV and/or ART 
knowledge inventories. 
† Crude 
‡ Adjusted for demographic variables (age, education, SES) 
§
 
Adjusted for demographic and clinical variables (age, education, SES, previous ART use, pregnancy intention, gestational 
age at enrolment, VL at enrolment, time on ART) 
 
  
  OR (95% CI) † P-value OR (95% CI) ‡ P-value OR (95% CI) § P-value 









































































































     
82 
 

























     
83 
 
APPENDIX A: HIV & ART KNOWLEDGE QUESTIONNAIRES 
Date completed: _ _ /_ _ _ / _ _ _ _                      Signed counsellor completing CRF: _______________________ 
Date of QC: _ _ /_ _ _ / _ _ _ _                             Signed measurement nurse: _________________ 
Visit Date: __ __/__ __ __/__ __ __ __ 
HIV/AIDS KNOWLEDGE INVENTORY :  
We are now going to ask you some questions about HIV/AIDS. Please circle your answer to each question below: 
 Score 0 1 2 4 
1.  Is HIV/AIDS spread by kissing? No Yes Don't Know Refuse 
2.  Must a person have many different partners to get HIV/AIDS? No Yes Don't Know Refuse 
3.  Can a pregnant woman give HIV/AIDS to her baby? No Yes Don't Know Refuse 
4.  Is HIV the virus that causes AIDS? No Yes Don't Know Refuse 
5.  Is there a cure for HIV/AIDS? No Yes Don't Know Refuse 
6.  Are there medications that a woman can take to protect her baby from getting HIV/AIDS? No Yes Don't Know Refuse 
7.  Can a woman give HIV/AIDS to her baby during breast feeding? No Yes Don't Know Refuse 
8.  Does formula feeding reduce the risk of a baby getting HIV? No Yes Don't Know Refuse 
9.  Do caesarian sections reduce the risk of a baby getting HIV? No Yes Don't Know Refuse 
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Visit Date: __ __/__ __ __/__ __ __ __ 
HIV/AIDS TREATMENT KNOWLEDGE INVENTORY 
We are now going to ask you some questions about HIV/AIDS treatment. Are the following statements TRUE or FALSE?  
Indicate by circling your answer for each statement. 
 Score 0 1 2 4 
1 Antiretroviral medication aims to reduce or suppress the activity of the HIV virus in the body. TRUE FALSE Don’t know Refuse 
2 Taking antiretroviral medications on schedule helps keep the right amount of medicine in one’s system. TRUE FALSE Don’t know Refuse 
3 Viral load measures the amount of HIV virus in the blood. TRUE FALSE Don’t know Refuse 
4 Sometimes lab results say that a person’s viral load is “undetectable.” This means that there is no virus left. TRUE FALSE Don’t know Refuse 
5 Taking antiretroviral therapy exactly as prescribed is likely to reduce viral load. TRUE FALSE Don’t know Refuse 
6 Taking antiretroviral therapy can reduce a child's risk of becoming HIV infected during pregnancy and delivery. TRUE FALSE Don’t know Refuse 
7 Taking antiretroviral therapy can reduce a child's risk of becoming HIV infected during breastfeeding. TRUE FALSE Don’t know Refuse 
8 If a person takes antiretroviral therapy and has a low viral load, they may be less likely to transmit the virus through having sex with an HIV-negative partner. TRUE FALSE Don’t know Refuse 
Date completed: __ __ /__ __ __ / __ __ __ __             Signed counsellor completing CRF: _______________________ 
Date of QC: __ __ /__ __ __ / __ __ __ __              Signed measurement nurse: _________________ 
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APPENDIX B: DEMOGRAPHIC CHARACTERISTICS AND MEDICAL HISTORY QUESTIONNAIRE 
 
Visit Date: __ __/__ __ __/__ __ __ __ 
1.  What is your date of birth? Day:____ Month :_______ Year:_______ 
2.  What is your age? Age:_________ (years) 
3.  What population group do you belong to? 
African = 1 
Indian = 2 
Coloured = 3 
White = 4 
Other = 5, specify: _________________ 
4.  What language do you speak at home? 
isiXhosa = 1 
isiZulu = 2 
Afrikaans = 3 
English = 4 
Other = 5  specify: ___________ 





6.  Are you currently working and or studying? 
No = 0  SKIP to Q8 
Yes = 1 
7.  
If yes, which of one the following best describes what you 
do? 
Choose one only 
Employed full-time = 1 
Employed part-time = 2 
Informal job/hawker = 3 
Attending school/learner = 4 
Attending tertiary education facility = 5 
8.  What is the MAJOR source of income for your household? 
Choose one only 
None = 0 
Full-time employment = 1 
Part-time employment = 2  
Informal employment = 3  
Disability grant = 4 
Social grant = 5 
Pension = 6 
Other grant = 7, specify type: _________ 
Other = 8, specify:__________________ 
Don’t know = 9 
9.  What kind of home do you live in? 
Shack/informal dwelling = 1 
Formal house = 2 
Flat/council home = 3 
Other = 4, specify: ____________ 
10.  
Does your house have the 
following: 
Read and answer for all 
a. A toilet inside 
No = 0 
Yes = 1 
b. Running water 
inside 
No = 0 
Yes = 1 
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c. Electricity inside 
No = 0 
Yes = 1 
d. A refrigerator 
No = 0 
Yes = 1 
e. A telephone 
No = 0 
Yes = 1 
f. A television 
No = 0 
Yes = 1 
11.  Including yourself, how many people (adults and children) live in your house? # of people: ________ 
12.  How many adults (aged 16 or older), including you, live in your house? # of adults:_________ 
13.  How many children (aged 15 and under) live in your house? # of children: _______ 
14.  How many times have you been pregnant (including current pregnancy)? # of pregnancies: __________ 
15.  Were you trying to have a baby when you found out you were pregnant (in this pregnancy)? 
No = 0 
Yes = 1 
Don’t Know = 9 
16.  How many children have you given birth to?  
# of children: __________ 
If 0, SKIP to Q21 
17.  How many of these children are living? # of children: __________ 
18.  How many of these children currently live with you? # of children: __________ 
19.  How many of your children have tested HIV-positive? # of HIV-positive children: _______ 
20.  
How many of these children who have tested HIV- positive 
are currently living? # of HIV-positive children currently alive: ___ 
21.  
Are you currently in a relationship? 
 
No = 0  SKIP to Q26 
Yes = 1 
22.  How would you describe your current relationship? 
Married = 1 
Not married, living together = 2 
Married, not living together = 3  
Not married, not living together = 4  
Other = 5, specify:____________ 
23.  How long have you been in this relationship? Duration in: Months_________   Years __________ 
24.  
Is your current partner the parent of any of your children? 
(including current pregnancy) 
No = 0 
Yes = 1 
25.  Have you disclosed your HIV status to your current partner? 
No = 0 
Yes = 1 
26.  
In the last 12 months have you had sexual 
relationships/sexual partners with people other than this 
partner? 
No = 0  SKIP to Q 29 
Yes = 1  
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27.  What is the nature of your other relationship(s)? 
Mark all that apply. 
a. Spouse/ married 
b. Boyfriend  
c. Casual Partner/One Night Stands  
d. Other, specify:____________ 
28.  Have you disclosed your HIV status to any of these other sexual partners? 
No = 0  
Yes = 1 
29.  Did you first test HIV positive in this pregnancy or before this pregnancy?  
In his pregnancy = 1  SKIP to 33 
Before this pregnancy = 2 
30.  When did you 1st test HIV-positive? Day:____ Month: _______Year:_______ 
 
31.  Why was this test conducted? 
Tested during pregnancy = 1 
VCT/Wanted to be tested = 2 
Diagnosed with TB = 3 
Admitted to the hospital = 4 
Other = 5, specify: ____________ 
32.  Were you pregnant when you first tested HIV-positive? No = 0  Yes = 1 
33.  Have you ever tested negative on an HIV test? 
No = 0  SKIP to Q37 
Yes = 1 
34.  When did you last test HIV-negative? Day:____ Month:_______Year:_______ 
35.  Why did you test at that time? 
Tested during pregnancy = 1 
VCT/Wanted to be tested = 2 
Diagnosed with TB = 3 
Admitted to the hospital = 4 
Other = 5, specify: ____________ 
36.  Were you pregnant at the time of that test? No = 0  Yes = 1 
37.  Have you told anyone that you are HIV-positive? 
No = 0  SKIP to Q40 
Yes = 1 
38.  
Which of your family members have you told about your 
HIV status? 
Please answer this question for each of the family 
members listed below.  
 
a.  Husband/partner 
No = 0  
Yes = 1 
N/A = 9 
b.  Mother 
No = 0  
Yes = 1 
N/A = 9 
c.  Father 
No = 0  
Yes = 1 
N/A = 9 
d.  Sister 
No = 0  
Yes = 1 
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N/A = 9 
e.  Brother 
No = 0  
Yes = 1 
N/A = 9 
f.  Daughter 
No = 0  
Yes = 1 
N/A = 9 
g.  Son 
No = 0  
Yes = 1 
N/A = 9 
h.  Uncle 
No = 0  
Yes = 1 
N/A = 9 
i.  Aunt 
No = 0  
Yes = 1 
N/A = 9 
j.  Male cousin 
No = 0  
Yes = 1 
N/A = 9 
k.  Female cousin 
No = 0  
Yes = 1 
N/A = 9 
l.  Other male family member 
No = 0  
Yes = 1 
N/A = 9 
m.  Other female family member 
No = 0  
Yes = 1 
N/A = 9 
39.  Aside from family members listed above, who else have you told about your HIV status? (read and answer for all ) 
a.  Health professionals 
No = 0  
Yes = 1 
b.  Support group 
No = 0  
Yes = 1 
c.  A sexual partner who does not live with you 
No = 0  
Yes = 1 
d.  Friends 
No = 0  
Yes = 1 
e.  Spiritual leader 
No = 0  
Yes = 1 
f.  Current or former employer 
No = 0  
Yes = 1 
g.  Public disclosure/ community 
No = 0  
Yes = 1 
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h.  Other, specify ___________________ 
No = 0  
Yes = 1 
40.  Have you ever been pregnant before this pregnancy? 
No = 0  SKIP to Q 46 
Yes = 1 
41.  
When you were pregnant before this pregnancy were you 
ever been given medication at the clinic to keep your baby 
from getting HIV infected? 
No = 0  SKIP to Q 46 
Yes = 1 
42.  If yes, during how many pregnancies have you received medication for this purpose? # of pregnancies: _______ 
43.  
For the ___ pregnancies that you received medication, For 
how many pregnancies did you take pills while you were 
pregnant and for how many pregnancies did you take pills 
only at delivery?: 
Only at Delivery (Nevirapine) #:___________ 
While you were pregnant (AZT)? #: _______ 
44.  When was the last time that you received medication for this purpose? Day:____ Month:_______Year:_______ 
45.  Where did you receive the medication the last time? Name of clinic: ________________ 
46.  Aside from when you were pregnant, have you ever taken ART in the past? 
No = 0  END 
Yes = 1 
47.  If yes, where did you receive ART the last time? Name of clinic____________________ 
48.  When did you start taking ART? Day:____ Month:_______Year:_______ 
49.  Are you still on ART? No = 0  Yes = 1 END 
50.  
 




Why did you stop taking ART? 
 
Circle all that apply 
a. I ran out of medicine and didn’t go for 
refills 
b. The medicine tastes bad 
c. I just forgot 
d. I was worried about the side effects 
e. I did not want others to notice me taking 
the medicine 
f. I was ill 
g. Didn’t think I needed it anymore 
h. Can stay healthy without it  
i. I felt the medicine might be harmful to me 
j. I felt depressed 
k. I was well 
l. There was too much medicine to take 
m. I was away from home   
n. I was busy with other things 
o. I learned that there are other ways to 
treat or cure HIV 
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Date completed: _ _ /_ _ _ / _ _ _ _     
Signed counsellor completing CRF: _______________________ 
Date of QC: _ _ /_ _ _ / _ _ _ _                 
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TITLE OF RESEARCH: Strategies to optimize antiretroviral therapy 
services for maternal & child health: the MCH-
ART study  
 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
We are from the University of Cape Town. You are being asked to take part in a study that is being 
conducted at the Gugulethu Midwife Obstetric Unit (MOU). The purpose of this study is to understand 
how to improve health care services for HIV-infected women during their pregnancy and after they 
deliver the baby.  
 
We know that it is important for their own health as well as the health of their baby, that HIV-positive 
women receive the HIV care and treatment that they need both during and after delivery. Information 
learned in this study will help us to improve HIV services for pregnant women. 
 
You are being asked to take part in this study because you are a pregnant woman who is HIV-positive 
and you are getting your pregnancy care here at the Gugulethu MOU. The purpose of this consent is to 
give you information to help you decide if you want to take part in this study.  
 
 
WHAT DO I HAVE TO DO IF I AGREE TO TAKE PART? 
If you agree to take part, you will do the following at today’s visit: 
 Answer questions about your household, medical history, partnership status, HIV testing 
history and disclosure status and previous use of HIV drugs. 
 Have 5mLs (1 teaspoon) of blood drawn from your arm so that we can check your viral 
load (this is the amount of HIV in your blood) 
 
NOTE: Blood drawn today for viral load testing is not part of your routine health care. This blood will 
be stored and tested at a later time. Results from these tests will not be available to you, the clinic, or 
the study staff. When the health care providers at the clinic need to check your viral load, they will 
take a separate blood specimen. When it is stored, your blood and test results will not have your name 
or any other way of identifying you attached to it. 
 
Review of medical records 
As part of this study, we will also be reviewing and abstracting information from your medical 
records. We are interested in learning about the HIV care and treatment that you receive during your 
pregnancy and after you delivered. We also want to learn about the pregnancy care you received as 
well as information about your delivery. 
  
All data that we review and abstract is confidential and no participant names are recorded on study 
documents. 
 
Contact for future study 
After the completion of this visit, it is possible that we will contact you again at your next clinic visit 
to take part in additional study visits like this one. At that time, you would be asked to review and sign 
another consent form. You can choose to not take part in these additional visits if you are asked. 
Document 1 
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WHAT ARE THE POTENTIAL RISKS? 
If you decide to participate, you may feel uncomfortable about some of the personal questions you are 
asked about your health or your pregnancy. You may refuse to answer any question that you do not 
want to answer.  There is some risk in sharing personal and medical information.  We will be careful 
to keep all your information as private as possible.   
 
Drawing blood is normally done as part of routine medical care and presents a slight risk of 




WHAT ARE THE POTENTIAL BENEFITS? 
There is no direct benefit to you if you take part in this study but if we identify any health care 
problem during the course of the study, we will make sure you are referred to the appropriate health 
care services. The information gained in this study may help to improve ART services for HIV-
infected pregnant women in Cape Town, the Western Cape Province, and across South Africa. 
 
 
WHAT ARE THE ALTERNATIVES TO TAKING PART?  
The alternative to taking part in this study is to continue with the standard of care for all HIV-positive 
pregnant women.  
 
 
WHAT ABOUT CONFIDENTIALITY? 
If you agree to take part, all information collected during the study will be kept strictly confidential. 
Your name will not be written on the study forms and will not be used in connection with any 
information or lab specimens that are collected as part of the study.  
 
All study materials will be stored in locked filing cabinets. Only study staff and personnel involved in 
routine audits will have access to these materials. All staff involved in data collection and management 
will get specific training in confidentiality. 
 
 
WILL I BE GIVEN ANYTHING FOR TAKING PART? 
No, there is no compensation for participating in the study today. 
 
 
ARE THERE ANY COSTS? 
There is no cost for being in this study. 
 
 
CAN I LEAVE THE STUDY? 
You have the right to decide not to not take part in the study, to refuse to answer any questions, or to 
withdraw from the study at any time without any penalty.  It will have no effect on the care that you 
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FUTURE USE OF SPECIMENS: 
We are specifically looking at your use of antiretroviral therapy during this study, and in particular the 
amount of HIV in your blood. However, the information and samples being collected from all 
participants may also help answer other questions about HIV in the future. If there is leftover blood at 
the end of this study, we may want to use your leftover blood so that other research studies can be 
done in the future.  If you agree to let us keep your leftover samples for future research, they may be 
kept in a locked freezer for up to 5 years. If we do use your samples in the future, your name or other 
identifiers will not be included with this information (as with the rest of the information we collect for 
this study). 
 
Please initial below to indicate whether or not you give permission for your specimens to be used for 
future research. 
 
______ (initial) I agree to have my specimens stored for future research by the investigators 
who are conducting this study. 
 
______ (initial) I do NOT agree to the storage of my blood after the end of this study. 
 
 
DO YOU HAVE ANY QUESTIONS? 
If there is anything that is unclear or if you need further information, please ask us and we will provide 
it.  
Do you have any questions? 
 
 
FOR ADDITIONAL INFORMATION: 
If you have any questions or have any problems while taking part in this research study, you should 
contact: 
Dr Landon Myer   
School of Public Health and Family Medicine  
Faculty of Health Sciences, University of Cape Town  
Tel: 021 406 6661; email: Landon.Myer@uct.ac.za  
 
If you have any questions about your rights as a research participant, you may contact the following 
member of the ethics committee: 
 Prof Marc Blockman  
Chair, Human Research Ethics Committee 
Faculty of Health Sciences, University of Cape Town 




CONSENT STATEMENT:   
I have read this form, or someone has read it to me.  I have been offered a copy of this consent form. I 
was encouraged and given time to ask questions.  I agree to be in this study.  I know that after 
choosing to be in this study, I may withdraw at any time.  My being in the study is voluntary. I 
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understand that whether or not I participate will not affect my health care services received today, or at 
any time in the future. 
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TITLE OF RESEARCH: Strategies to optimize antiretroviral therapy 
services for maternal & child health: the MCH-
ART study  
 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
We are from the University of Cape Town. You are being asked to take part in a study that is being 
conducted at the Gugulethu Midwife Obstetric Unit (MOU).  The purpose of this study is to 
understand how to improve health care services for HIV-infected women during their pregnancy and 
after they deliver the baby.  
 
We know that it is important for their own health as well as the health of their baby, that HIV-positive 
women receive the HIV care and treatment that they need both during and after delivery. Information 
learned in this study will help us to improve HIV services for pregnant women. 
 
You are being asked to take part in this study because you are a pregnant woman with known HIV 
infection who is about to start taking HIV drugs (antiretroviral therapy). The purpose of this consent 
form is to give you information to help you decide if you want to take part in this study.  
 
 
WHAT DO I HAVE TO DO IF I AGREE TO TAKE PART? 
If you agree to take part, you will come in for up to 3 visits. These visits will take place today while 
you are in the clinic, during your third trimester and within one week of delivering your baby. Each 
visit will take about 30-45 minutes. 
 
At the two visits that are conducted while you are pregnant, you will do the following: 
 Answer questions about your recent pregnancy- and HIV-related health care, HIV disclosure, 
and use of HIV drugs (including side effects and adherence).  
o At different visits, we will ask you additional questions about HIV, stigma, social 
support, infant feeding practices, family planning, experiences of partner violence, and 
mental health (including drug and alcohol use). 
 Have 5mLs (1 teaspoon) of blood drawn from your arm each time so that we can check your 
viral load (amount of HIV in your body) 
 
One-week after delivery 
One week after you give birth to your baby, you will come to the clinic for a visit that will include the 
following: 
 Answer questions about your recent pregnancy- and HIV-related health care, HIV disclosure, 
and use of HIV drugs (including side effects and adherence).  
o At this visit, we will ask you additional questions about family planning after delivery, 
how you felt about the HIV care that you received, infant feeding practices and infant 
health care. 
 Have 5mLs (1 teaspoon) of blood drawn from your arm so that we can check your viral load 
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NOTE: Blood drawn today for viral load testing is not part of your routine health care. This blood will 
be stored and tested at a later time. Results from these tests will not be available to you, the clinic, or 
the study staff. When the health care providers at the clinic need to check your viral load, they will 
take a separate blood specimen. When it is stored, your blood and test results will not have your name 
or any other way of identifying you attached to it. 
 
Contact for future study 
After the completion of the visit one week after delivery, it is possible that we will ask to see whether 
you would like to participate in a further research study that aims to understand how best to deliver 
health care services to HIV-positive mothers and their children. At that time, you will be asked to 




WHAT ARE THE POTENTIAL RISKS? 
You may feel uncomfortable about some of the personal questions you are asked.  You may refuse to 
answer any question that you do not want to answer.  There is some risk in sharing personal and 
medical information.  We will be careful to keep all your information as private as possible.   
 
Drawing blood is normally done as part of routine medical care and presents a slight risk of 




WHAT ARE THE POTENTIAL BENEFITS? 
There is no direct benefit to you if you take part in this study. The information gained in this study 
may help to improve ART services for HIV-infected pregnant women in Cape Town, the Western 
Cape Province, and across South Africa. 
 
 
WHAT ARE THE ALTERNATIVES TO TAKING PART?  
The alternative to taking part in this study is to continue with the standard of care for all HIV-positive 
pregnant women.  
 
 
WHAT ABOUT CONFIDENTIALITY? 
If you agree to take part, all information collected during the study will be kept strictly confidential. 
Your name will not be written on the study forms and will not be used in connection with any 
information or lab specimens that are collected as part of the study.  
 
All study materials will be stored in locked filing cabinets. Only study staff and personnel involved in 
routine audits will have access to these materials. All staff involved in data collection and management 
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WILL I BE GIVEN ANYTHING FOR TAKING PART? 
At the end of each visit, you will be given a R150 grocery voucher.  
 
ARE THERE ANY COSTS? 
There is no cost for being in this study. 
 
 
CAN I LEAVE THE STUDY? 
You have the right to decide not to not take part in the study, to refuse to answer any questions, or to 
withdraw from the study at any time without any penalty.  It will have no effect on the care that you 
receive at the Gugulethu MOU or any other health facility. 
 
 
FUTURE USE OF SPECIMENS: 
We are specifically looking at your use of antiretroviral therapy during this study, and in particular the 
amount of HIV in your blood. However, the information and samples being collected from all 
participants may also help answer other questions about HIV in the future. If there is leftover blood at 
the end of this study, we may want to use your leftover blood so that other research studies can be 
done in the future.  If you agree to let us keep your leftover samples for future research, they may be 
kept in a locked freezer for up to 5 years. If we do use your samples in the future, your name or other 
identifiers will not be included with this information (as with the rest of the information we collect for 
this study). 
 
Please initial below to indicate whether or not you give permission for your specimens to be used for 
future research. 
 
______ (initial) I agree to have my specimens stored for future research by the investigators 
who are conducting this study. 
 
______ (initial) I do NOT agree to the storage of my blood after the end of this study. 
 
 
DO YOU HAVE ANY QUESTIONS? 
If there is anything that is unclear or if you need further information, please ask us and we will provide 
it.  
Do you have any questions? 
 
 
FOR ADDITIONAL INFORMATION: 
If you have any questions or have any problems while taking part in this research study, you should 
contact: 
Dr Landon Myer   
School of Public Health and Family Medicine  
Faculty of Health Sciences, University of Cape Town  
Tel: 021 406 6661; email: Landon.Myer@uct.ac.za  
 




If you have any questions about your rights as a research participant, you may contact the following 
member of the ethics committee: 
 Prof Marc Blockman  
Chair, Human Research Ethics Committee 
Faculty of Health Sciences, University of Cape Town 
Tel: 021 406 6338 
 
 
CONSENT STATEMENT:   
I have read this form, or someone has read it to me.  I have been offered a copy of this consent form. I 
was encouraged and given time to ask questions.  I agree to be in this study.  I know that after 
choosing to be in this study, I may withdraw at any time.  My being in the study is voluntary. I 
understand that whether or not I participate will not affect my health care services received today, or at 
any time in the future. 
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TITLE OF RESEARCH: Strategies to optimize antiretroviral therapy 
services for maternal & child health: the MCH-
ART study  
 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
We are from the University of Cape Town. You are being asked to take part in a study that is being 
conducted at the Gugulethu Midwife Obstetric Unit (MOU). The purpose of this study is to compare 
two different ways of providing HIV treatment to women after they deliver a baby.   
 
We know that it is important for their own health as well as the health of their baby, that HIV-positive 
women receive the HIV care and treatment that they need both during and after delivery. Information 
learned in this study will help us to improve HIV services for pregnant women. 
 
You are being asked to take part in this study because you are a pregnant woman with known HIV 
infection who is about to start taking HIV drugs. The purpose of this consent form is to give you 
information to help you decide if you want to take part in this study.  
 
 
WHAT DO I HAVE TO DO IF I AGREE TO TAKE PART? 
If you agree to take part, you will be randomized (like a flip of a coin) to one of two places to receive 
your ART, as described below:  
 
1. MCH-focused ART services group: Women assigned to this group will continue to receive 
HIV care and medicines here, at the MOU, as they did during their pregnancy. When they have 
stopped breastfeeding, women in this group will be referred to their nearest general ART 
clinic. 
 
2. General ART services group: Women assigned to this group will be referred to the nearest 
ART clinic for HIV care and to continue their HIV medicines. 
 
“Randomised” means that you will have a 50% chance of being in the group that will receive on-site 
care. You will also have a 50% chance of being in the group that receives referred care. Neither the 
study staff nor you can choose which group you will be assigned to. The decisions are made by a 
computer and put into an envelope. The staff does not know which group is in each envelope. 
 
This randomization will occur today and you will then come in for up to 4 additional study 
measurement visits at 6 weeks after delivery and 6, 9, and 12 months after delivery. Each visit will 
take about 30-60 minutes. 
 
These visits will include the following: 
 Answer questions about your recent pregnancy- and HIV-related health care, HIV disclosure, 
and use of HIV drugs (including side effects and adherence).  
o At selected visits, we will ask you additional questions about HIV, stigma, and mental 
health (including drug and alcohol use), family planning, infant feeding practices, 
infant health care and how you feel about the HIV care that you have received. 
Document 3 
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 Have 5mLs (1 teaspoon) of blood drawn from your arm so that we can check your viral load 
(amount of HIV in your body) 
 
NOTE: Blood drawn today for viral load testing is not part of your routine health care. This blood will 
be stored and tested at a later time. Results from these tests will not be available to you, the clinic, or 
the study staff. When the health care providers at the clinic need to check your viral load, they will 
take a separate blood specimen. When it is stored, your blood and test results will not have your name 
or any other way of identifying you attached to it. 
 
At the last visit, we will also draw blood from your baby: 
 Baby will undergo a heelstick to collect blood to check your baby’s HIV status. 
o We will return the results of this test to you as soon as it is available. 
 
 
WHAT ARE THE POTENTIAL RISKS? 
You may feel uncomfortable about some of the personal questions you are asked.  You may refuse to 
answer any question that you do not want to answer.  There is some risk in sharing personal and 
medical information.  We will be careful to keep all your information as private as possible.   
 
Drawing blood is normally done as part of routine medical care and presents a slight risk of 




WHAT ARE THE POTENTIAL BENEFITS? 
There is no direct benefit to you if you take part in this study, but if we identify any health care 
problem during the course of the study, we will make sure you are referred to the appropriate health 
care services. In addition, the information gained in this study may help to improve ART services for 
HIV-infected pregnant women in Cape Town, the Western Cape Province, and across South Africa. 
 
 
WHAT ARE THE ALTERNATIVES TO TAKING PART?  
The alternative to taking part in this study is to continue with the standard of care for all HIV-positive 
pregnant women, which means you will be referred from the MOU to your nearest general ART clinic 
as soon as possible.  
 
 
WHAT ABOUT CONFIDENTIALITY? 
If you agree to take part, all information collected during the study will be kept strictly confidential. 
Your name will not be written on the study forms and will not be used in connection with any 
information or lab specimens that are collected as part of the study.  
 
All study materials will be stored in locked filing cabinets. Only study staff and personnel involved in 
routine audits will have access to these materials. All staff involved in data collection and management 
will get specific training in confidentiality. 
 
 




WILL I BE GIVEN ANYTHING FOR TAKING PART? 
At the end of each visit, you will be given a R150 grocery voucher.  
 
 
ARE THERE ANY COSTS? 
There is no cost for being in this study. 
 
 
CAN I LEAVE THE STUDY? 
You have the right to decide not to not take part in the study, to refuse to answer any questions, or to 
withdraw from the study at any time without any penalty.  It will have no effect on the care that you 
receive at the Gugulethu MOU or any other health facility. 
 
 
FUTURE USE OF SPECIMENS: 
We are specifically looking at your use of antiretroviral therapy during this study, and in particular the 
amount of HIV in your blood. However, the information and samples being collected from all 
participants may also help answer other questions about HIV in the future. If there is leftover blood at 
the end of this study, we may want to use your leftover blood so that other research studies can be 
done in the future.  If you agree to let us keep your leftover samples for future research, they may be 
kept in a locked freezer for up to 5 years. If we do use your samples in the future, your name or other 
identifiers will not be included with this information (as with the rest of the information we collect for 
this study). 
 
Please initial below to indicate whether or not you give permission for your specimens to be used for 
future research. 
 
______ (initial) I agree to have my specimens stored for future research by the investigators 
who are conducting this study. 
 
______ (initial) I do NOT agree to the storage of my blood after the end of this study. 
 
 
DO YOU HAVE ANY QUESTIONS? 
If there is anything that is unclear or if you need further information, please ask us and we will provide 
it.  
Do you have any questions? 
 
 
FOR ADDITIONAL INFORMATION: 
If you have any questions or have any problems while taking part in this research study, you should 
contact: 
Dr Landon Myer   
School of Public Health and Family Medicine  
Faculty of Health Sciences, University of Cape Town  
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Tel: 021 406 6661; email: Landon.Myer@uct.ac.za  
 
If you have any questions about your rights as a research participant, you may contact the following 
member of the ethics committee: 
 Prof Marc Blockman  
Chair, Human Research Ethics Committee 
Faculty of Health Sciences, University of Cape Town 
Tel: 021 406 6338 
 
 
CONSENT STATEMENT:   
I have read this form, or someone has read it to me.  I have been offered a copy of this consent form. I 
was encouraged and given time to ask questions.  I agree to be in this study.  I know that after 
choosing to be in this study, I may withdraw at any time.  My being in the study is voluntary. I 
understand that whether or not I participate will not affect my health care services received today, or at 
any time in the future. 
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APPENDIX E: STUDY ETHICAL CLEARANCE 
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2. Aims and Scope 
3. Manuscript Categories and Requirements 
4. Preparing the Submission 
5. Editorial Policies and Ethical Considerations 
6. Author Licensing 
7. Publication Process After Acceptance 
8. Post Publication 
9. Editorial Office Contact Details 
 
1. SUBMISSION 
Please carefully read through the Instructions for Authors and prepare your manuscript according to the 
guidelines, including structuring it manuscript based on the chosen article category. Manuscripts that do not 
follow the instructions may be returned to the authors for corrections. 
Authors should kindly note that submission implies that the content has not been published or submitted for 
publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. 
Once the submission materials have been prepared in accordance with the Author Guidelines, 
manuscripts should be submitted online at https://mc.manuscriptcentral.com/jias. The submission 
system will prompt authors to use an ORCID iD (a unique author identifier) to help distinguish their 
work from that of other researchers. Click here to find out more. 
You will be asked to suggest potential peer reviewers for your manuscript: they should be experts in the field 
and be able to provide an objective assessment of the manuscript. Any suggested peer reviewers should not 
have published with any of the authors of the manuscript within the past five years, should not be current 
collaborators, and should not be members of the same institution. Suggested reviewers will be considered 
alongside potential reviewers identified by the Editorial team. 
Click here for more details on how to use ScholarOne. 
 
2. AIMS AND SCOPE 
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The JIAS welcomes submissions on HIV-related topics from across all scientific disciplines, including but not 
limited to: 
 
• Basic and biomedical sciences 
• Behavioural sciences 
• Epidemiology 
• Clinical sciences 
• Health economics and health policy 
• Operations research and implementation sciences 
• Social sciences and humanities, including political sciences and media 
The JIAS prioritizes submissions from operational research and implementation science as publication of such 
material can provide valuable information on various algorithms for monitoring and providing support for 
comprehensive, yet affordable and sustainable treatment, prevention and care programmes in different 
contexts. 
 
Submission of HIV research carried out in low- and middle-income countries is strongly encouraged. 
 
3. MANUSCRIPT CATEGORIES AND REQUIREMENTS 
The JIAS accepts submissions in the following categories: 
• Research 




• Letter to the Editor 
• Viewpoint 
Research - full reports of data from original research studies 
 
Headings: Introduction, Methods, Results, Conclusions 
Word limit: 350 words 
 
Main text: 
Headings: Introduction, Methods, Results, Discussion, Conclusions 
Word limit: 3500 words 
Numbers of figures and tables: Unlimited 
Additional files: Yes 
Download the manuscript template 
 
Short report - brief reports of data from original research, such as follow-up or confirmatory studies, 
case series and negative results 
 




Headings: Introduction, Methods, Results and discussion, Conclusions 
Word limit: 350 words 
 
Main text: 
Headings: Introduction, Methods, Results and discussion, Conclusions 
Word limit: 2500 words 
Numbers of figures and tables: 4 
Additional files: No 
Download the manuscript template 
 
Review - comprehensive, authoritative descriptions and summaries of a specific subject area providing 
a systematic and substantial overview of the field 
Abstract: 
Headings: Introduction, Methods (if applicable), Results and discussion (if applicable, otherwise Discussion 
only), Conclusions 
Word limit: 350 words 
 
Main text: 
Headings: Introduction, Methods (if applicable), Results and discussion (if applicable, otherwise Discussion 
only), Conclusions 
Word limit: 5000 words 
Numbers of figures and tables: Unlimited 
Additional files: Yes 
Download the manuscript template 
 
Debate - presentation of an evidence-based argument 
Abstract: 
Headings: Introduction, Discussion, Conclusions 
Word limit: 350 words 
 
Main text: 
Headings: Introduction, Discussion, Conclusions 
Word limit: 3500 words 
Numbers of figures and tables: 4 
Additional files: No 
Download the manuscript template 
 
Commentary - focused and opinionated articles on important and timely issues, no original data 
Abstract: 
Headings: Introduction, Discussion, Conclusions 
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Word limit: 350 words 
 
Main text: 
Headings: Introduction, Discussion, Conclusions 
Word limit: 2500 words 
Numbers of figures and tables: 1 
Additional files: No 
Download the manuscript template 
 






Word limit: 500 words 
Numbers of figures and tables: None 
Additional files: No 
Download the manuscript template 
 







Word limit: 1000 words 
Numbers of figures and tables: 1 
Additional files: No 
Download the manuscript template 
 
4. PREPARING THE SUBMISSION 
Cover letter 
In the cover letter, please explain why your manuscript should be published in the journal. If necessary, address 
any issues relating to our editorial policies .and declare any competing interests (see Editorial Policies and 
Ethical Considerations) 
Parts of the Manuscript 
The manuscript should be submitted as a main text file including figures and appendices and supporting 
information should be supplied as separate files. 
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Main Text File 
The text file should be presented in the following order: 
1. Title page; 
2. Keywords; 
3. Abstract; 
4. Main text; 







The title should not contain abbreviations, except commonly used abbreviations such as HIV or AIDS 
(see Wiley's best practice SEO tips ). 
On the title page, you should mention the title of the manuscript, list all authors' names in full, and list any study 
groups if applicable. Each authors' affiliation should be numbered in superscript consecutively and listed 
underneath, including department, institution, city and country. 
The corresponding author should be marked with the symbol § in superscript and full contact details should be 
provided, including a telephone number with country code. Authors who have contributed equally to the work 
should be marked with the symbol * in superscript. Deceased authors should be marked with the symbol ^ in 
superscript. The email addresses of all authors should be listed by their initials. 
 
Keywordsl 
Pease provide six keywords. Keywords should be taken from those recommended by the US National Library of 
Medicine's Medical Subject Headings (MeSH) browser list at https://www.nlm.nih.gov/mesh/. Preferably 
alternate words to those found in the abstract in order to improve search hits for the article in repositories. 
Abstract 
The Abstract should not exceed 350 words and should be structured according to the headings of the selected 
article category (see above), excluding the heading “Discussion” for Research articles. Avoid using 
abbreviations and do not cite references in the Abstract. If you are reporting results from a controlled health 
care intervention, please include your trial registry, together with your unique identifying number at the end of 




The Introduction section should introduce the topic to readers without specialist knowledge in that area and 




The Methods section should include all information necessary to repeat the study, in particular, the study 
design, how data was collected and analyzed, clarifying the choice of methods that were made. If applicable, 
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you should describe the setting of the study, the dates the study were conducted, and the sample or 
participants, as well as necessary power calculations and materials, including statistical packages, used. 
Interventions and programmes should be described in detail. Generic names for drugs or any molecules should 
be used. 
 
All studies involving humans or animals require a statement on ethical approval, and for the former, the consent 
procedure that was followed. Please include the names of the ethics review board(s) that approved the study. If 
the research study was specific to one sex/gender, the reasons for this should be clearly stated. 
 
Results 
This section should include only data and findings from the authors' study. Presentation of statistical results 
should mention confidence intervals and levels of significance where appropriate. Quotes from qualitative study 
participants of less than three lines should be quoted in the text using quotation marks. For quotes longer than 
three lines, place the quote in a separate, indented paragraph and introduce it with a colon. No quotation marks 
are needed in this case. Details of the participant can be added in round brackets following the quote, but 
should not contain identifiable information to ensure confidentiality. Clarifications within the quotation should be 
placed in square brackets. 
 
Submitting authors are strongly encouraged to include data disaggregated by sex (and, whenever possible, by 
race) and provide a comprehensive analysis of gender and racial differences. The authors should include the 
number and percentage of men, women and, if appropriate, transgender persons who participated in the 
research study. Anatomical and physiological differences between men and women (height, weight, body fat-to-
muscle ratios, cell counts, hormonal cycles, etc.), as well as social and cultural variables (socio-economic, 
education, access to care, etc.), should be taken into consideration in the presentation of data and/or analysis 
of the results. 
 
Discussion 
In the Discussion section, you should discuss your main findings and place these within the context of the 
current body of knowledge in the field. Limitations of the study, for example, selection bias, can also be 
discussed, and should address how these influence the results and conclusions. If statistically significant 
differences were found between men and women or between different racial or cultural groups in the effects of 




In your Conclusions section, state your key messages from the study and explain their importance and 
relevance, as well as implications. Future studies and recommendations can be included in this section. The 
conclusions drawn must be strictly based on the data provided. 
 
Conflict of Interest Statement 
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